




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C07D 239/48, 239/95, 403/04 C07D 401/04, 471/04 A61K 31/505	A1	(11) International Publication Number: WO 90/12790 (43) International Publication Date: 1 November 1990 (01.11.90)
(21) International Application Number: PCT/GB90/00595 (22) International Filing Date: 19 April 1990 (19.04.90) (30) Priority data: 8909054.2 21 April 1989 (21.04.89) GB 8910548.0 8 May 1989 (08.05.89) GB (71) Applicant: IMPERIAL CHEMICAL INDUSTRIES PLC [GB/GB]; Imperial Chemical House, Millbank, London SW1P 3JF (GB). (72) Inventors: HARGREAVES, Rodney, Brian ; 42 Deva Close, Poynton, Cheshire SK12 1HH (GB). MAR- SHALL, Paul, William ; 26 Astbury Lane Ends, Conglet- on, Cheshire CW12 3AY (GB). MCLOUGHLIN, Ber- nard, Joseph ; 7 Pexhill Drive, Broken Cross, Maccles- field, Cheshire SK10 3LP (GB). MILLS, Stuart, Dennett ; 17 Harrington Drive, Gawsworth, Macclesfield, Chesh- ire SK11 9RD (GB).	(74) Agent: SMITH, Stephen, Collyer; ICI Legal Department: Patents, P.O. Box 6, Shire Park, Bessemer Road, Wel- wyn Garden City, Hertfordshire AL7 1HD (GB). (81) Designated States: AT (European patent), AU, BB, BE + (European patent), BG, CH (European patent), DE (Eu- ropean patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European pa- tent), HU, IT (European patent), JP, KR, LK, LU (Euro- pean patent), MC, MW, NL (European patent), NO, RO, SD, SE (European patent), SU. Published <i>With international search report.</i>	

(54) Title: PYRIMIDINE DERIVATIVES



(57) Abstract

This invention concerns novel aminopyrimidinium salts of the formula (I), in which R¹ is alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl or cycloalkyl-alkyl; one of R² and R⁶ is a basic group selected from amino, alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R² and R⁶ is hydrogen, alkyl, alkenyl, alkoxyalkyl, phenyl, phenylalkyl, cycloalkyl or cycloalkyl-alkyl; or both of R² and R⁶ are basic groups as mentioned above; and R⁵ is hydrogen, (1-4C)alkyl or (3-6C)alkyl; or R² is a basic group as mentioned above, and R⁵ and R⁶ together form alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring; R⁴ is hydrogen, alkyl, cycloalkyl-alkyl, alkenyl, alkynyl or phenylalkyl; or R⁴ is an optionally substituted alkylene or alkenylene linked to the nitrogen atom of the groupe Q.A.N-, either of which linking groups may thereby complete a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group -A.N-; A is a direct bond to the group -N(R⁴)- or is alkylene or oxyalkylene; Q is a pyridyl, furyl, thienyl or phenyl moiety; and Y is a physiologically acceptable anion; but excluding a number of compounds specified hereinafter. The invention also includes certain closely related anhydro-base derivatives which, like the formula (I) compounds, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing the formula (I) compound (or a related anhydro-base) as active ingredient, and processes for the manufacture of the various novel compounds.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

PYRIMIDINE DERIVATIVES

Technical Field

This invention concerns novel heterocyclic compounds and, more particularly, novel aminopyrimidine derivatives which possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node), pharmaceutical compositions containing such a derivative as active ingredient, and processes for the manufacture of and medical use of the said derivatives.

Background to Invention

Although numerous compounds are known to have medically useful effects on the cardiovascular system, hitherto there have not existed satisfactory agents which modulate the action of the sino-atrial node in warm-blooded animals such as man in a beneficial, selective and medically useful manner so that the agents are useful in treating cardiovascular disorders associated with an inappropriately elevated heart rate (that is by having a bradycardic effect) and yet have minimal effects on other haemodynamic parameters such as blood pressure or cardiac output. It is an object of the invention to provide such an agent which has inter alia bradycardic properties.

Pyrimidine derivatives have been extensively studied in the search for new pharmacologically active agents. A series of aminopyrimidine derivatives has been described as having cardiotonic properties (US Patent Ser. no. 4,725,600). Various 4-aminopyrimidinium salts have been described as antifungal and anti-bacterial agents (US Patent Ser. no. 4,339,453). The present invention is based on the unexpected and beneficial sino-atrial node modulatory effects of a novel series of aminopyrimidine derivatives of formula I defined below.

Disclosure of Invention

According to the invention there is provided an aminopyrimidine derivative of the formula I (set out hereinafter, together with the other chemical formulae appearing herein) wherein: R^1 is (1-10C)alkyl, (3-6C)alkenyl, (4-7C)cycloalkyl, phenyl,

- 2 -

phenyl(1-4C)alkyl or (3-6C)cycloalkyl-(1-4C)alkyl;
one of R^2 and R^6 is a basic group selected from amino,
(1-6C)alkylamino, dialkylamino of up to eight carbon atoms,
pyrrolidino, piperidino and morpholino; and the other of R^2 and R^6 is
hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl,
phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl;
or both of R^2 and R^6 are basic groups independently selected from the
above defined basic groups; and R^5 is hydrogen, (1-4C)alkyl or
(3-6C)alkenyl;
or R^2 is a basic group as defined above, and R^5 and R^6 together form
(3-6C)alkylene or, together with the appendant carbon atoms of the
pyrimidine ring, complete a benzene ring;
 R^4 is hydrogen, (3-6C)cycloalkyl-(1-4C)alkyl, (1-6C)alkyl,
(3-6C)alkenyl, (3-6C)alkynyl or phenyl(1-4C)alkyl; or R^4 is a
(1-4C)alkylene or (2-4C)alkenylene linked to the nitrogen atom of the
group Q.A.N-, either of which linking groups may optionally bear a
(1-4C)alkyl, phenyl or phenyl(1-4C)alkyl substituent and either of
which linking groups thereby completing a ring including two adjacent
carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen
atom of the group -A.N-; A is a direct bond to the the group $-N(R^4)-$
or is (1-6C)alkylene or is oxy(2-6C)alkylene in which the oxy group is
at least 2 carbon atoms away from the group $-N(R^4)-$; Q is a pyridyl,
furyl, thienyl or phenyl moiety;
Y is a physiologically acceptable anion;
and wherein any one or more of said phenyl or benzene moieties may
optionally be unsubstituted or bear one or more substituents
independently selected from halogeno, (1-4C)alkyl, (3-6C)alkenyl,
(1-4C)alkoxy, cyano, trifluoromethyl, nitro, carboxy,
(1-4C)alkylamino, dialkylamino of up to six carbon atoms,
(1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl and
(1-4C)alkylenedioxy;
but excluding those compounds in which:
(a) R^1 is alkyl, R^2 is amino or alkylamino, R^4 is hydrogen or alkyl,
 R^5 is hydrogen or alkyl, R^6 is hydrogen or phenyl optionally bearing
an alkyl or alkoxy substituent, A is a direct link and Q is phenyl
optionally bearing an alkyl or alkoxy substituent;
(b) R^1 is methyl or ethyl, R^2 is amino, R^4 and R^5 are hydrogen, R^6 is

methyl, and Q.A- is unsubstituted phenyl; r
(c) R^1 , R^5 and R^6 are methyl, R^2 is methylamino, R^4 is hydrogen and
Q.A- is 3,5-dimethylphenyl; R^2 is methylthio, R^1 , R^4 and R^6 are
methyl; and, in any of which, Y has the meaning stated above.

It will be understood that when R^4 is hydrogen, or when R^2
or R^6 is amino or alkylamino, the amino derivatives of the invention
may exist in another tautomeric form to that depicted in formula I, or
in a mixture of one or more of the possible tautomeric forms. It will
also be understood that when one of the substituents in the formula I
compounds contains a chiral centre, the compounds of the invention may
exist in, and be isolated in, optically active or racemic form. The
invention includes any tautomeric, optically active or racemic form of
a compound of formula I which possesses the afore-mentioned beneficial
pharmacological effects.

The compounds of formula I are quaternary salts and in some
cases, for example, when R^2 or R^6 is alkylamino and the other of R^2
and R^6 has any of the meanings defined above, may be converted, for
example by treatment with an quaternary ammonium hydroxide (and
especially one in macroreticular resin form) to the corresponding
non-ionic anhydro-base forms of the formula Ia or Ib, respectively,
(or to a tautomeric form thereof when R^4 is hydrogen or when the other
of the groups R^2 and R^6 is amino or alkylamino). Such non-ionic forms
of the formula Ia or Ib in which alk stands for (1-6C)alkyl are
provided as a further feature of the invention and may readily be
reconverted to the quaternary salt form, for example, by treatment
with the appropriate acid of the formula H.Y.

A particular value for R^1 when it is alkyl is, for example,
(1-7C)alkyl, such as methyl, ethyl, propyl, butyl, pentyl or heptyl,
of which values methyl and ethyl are generally preferred.

A particular value for R^2 or R^6 when it is alkyl is, for
example, methyl, ethyl, propyl, butyl or isobutyl.

A particular value for R^1 , R^2 , R^4 , R^5 or R^6 when it is
alkenyl is, for example, allyl, but-2-enyl, but-3-enyl,
2-methyl-2-propenyl or pentenyl.

A particular value for R^1 when it is cycloalkyl is, for
example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or

cycloheptyl, and for R^2 or R^6 is, for example, cyclopropyl, cyclobutyl, cyclopentyl or cycl hexyl.

A particular value for R^1 , R^2 , R^4 or R^6 when it is phenyl(1-4C)alkyl or for a phenyl(1-4C)alkyl substituent which is a part of R^4 is, for example, benzyl, 1-phenylethyl or 2-phenylethyl.

A particular value for R^1 , R^2 , R^4 or R^6 when it is cycloalkyl-alkyl is, for example, cyclopropyl-methyl, cyclopentyl-methyl, cyclohexylmethyl or 2-(cyclohexyl)ethyl.

A particular value for R^5 when it is alkyl is, for example, methyl, ethyl, propyl, isopropyl or butyl.

A particular value for R^2 or R^6 when it is alkoxyalkyl is for example, methoxymethyl, ethoxymethyl, 2-methoxyethyl or 2-ethoxyethyl.

A particular value for R^5 and R^6 when together they form (3-6C)alkylene is, for example, trimethylene, tetramethylene, pentamethylene or a group of the formula $-\text{CH}_2\cdot\text{C}(\text{CH}_3)_2\cdot\text{CH}_2-$ or $-\text{CH}_2\cdot\text{C}(\text{CH}_3)_2\cdot\text{CH}_2\cdot\text{CH}_2-$.

A particular value for R^4 when it is alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or pentyl, of which values methyl and especially ethyl are particularly preferred.

A particular value for R^4 when it is alkynyl is, for example, prop-2-ynyl or but-2-ynyl.

A particular value for R^2 or R^6 when it is alkylamino is, for example, methylamino, ethylamino, propylamino or butylamino, and when it is dialkylamino is, for example, dimethylamino, diethylamino, methylpropylamino or dipropylamino.

A particular value for R^4 when it is alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N- is for example, methylene, ethylidene, ethylene, isopropylidene, trimethylene, tetramethylene, vinylene or 1,3-propenylene; and a particular value for a substituent which may be present on such a linking group is, for example, methyl, ethyl, propyl, butyl, phenyl, benzyl, 1-phenylethyl or 2-phenylethyl (the benzene moiety of any of the last four groups themselves optionally substituted as defined above).

A particular value for A when it is alkylene is, for example, methylene, ethylene, trimethylene or tetramethylene, any of

- 5 -

which may optionally bear one or two methyl substituents; and when it is oxyalkylene is, for example, oxyethylene, oxytrimethylene, methyleneoxyethylene or ethyleneoxyethylene, any of which may optionally bear one or two methyl substituents.

A preferred value for A is, for example, when it is a direct bond, methylene or ethylene.

Particular values for optional substituents which may be present as defined hereinabove on a phenyl or benzene moiety include, by way of example:

for halogeno, fluoro, chloro and bromo;

for alkyl, methyl, ethyl and propyl;

for alkenyl, allyl and 2-methyl-2-propenyl;

for alkoxy, methoxy, ethoxy and propoxy;

for alkylamino, methylamino and ethylamino;

for dialkylamino, dimethylamino and diethylamino;

for alkylthio, methylthio and ethylthio;

for alkylsulphinyl, methylsulphinyl and ethylsulphinyl;

for alkylsulphonyl, methylsulphonyl and ethylsulphonyl; and

for alkylenedioxy, methylenedioxy and isopropylidenedioxy.

In general, it is preferred that, when Q is a phenyl or benzene moiety it is unsubstituted or bears up to three substituents.

Specific values for Q include, for example, phenyl, 4-chlorophenyl, 4-methylphenyl, 2-nitrophenyl, 2-methylphenyl, 2-carboxyphenyl, 2-methoxyphenyl, 4-methylthiophenyl, 2,5-dinitrophenyl, 2,5-dimethylphenyl, 3,5-dimethylphenyl, 3,5-dichlorophenyl, 3,5-dibromophenyl, 3,5-dimethoxyphenyl, furyl, thienyl and pyridyl.

Specific values for the group $Q.A.N(R^4)$ when R^4 is alkylene or alkenylene include, for example, 1-indolyl, 3-methyl-1-indolyl, 3-ethyl-1-indolyl, 3-propyl-1-indolyl, 5-bromo-1-indolyl, 5-chloro-1-indolyl, 5-fluoro-1-indolyl, 5-methyl-1-indolyl, 5-methoxy-1-indolyl, 1-indolinyl, 3-methyl-1-indolinyl, 3-ethyl-1-indolinyl, 3-isopropyl-1-indolinyl, 1-indolinyl, 1,2,3,4-tetrahydro-1-quinolyl, 1,2,3,4-tetrahydro-2-isoquinolyl and 3,4-dihydro-1,4-benzoxazin-4-yl.

By way of example, a preferred value for R^6 is, alkylamino such as methylamino or ethylamino, for R^5 is hydrogen, for Q is phenyl (optionally substituted as indicated above) and for A is a direct

link.

A group of compounds of the invention which are of particular interest comprises those compounds of the formula II wherein:

Ra is (1-10C)alkyl, (3-6C)alkenyl, phenyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl; Rb is (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl, amino, (1-4C)alkylamino or dialkylamino of up to 6 carbon atoms; Rc is hydrogen, (3-6C)cycloalkyl-(1-4C)alkyl, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl or phenyl(1-4C)alkyl; or Rc is (1-4C)alkylene or (2-4C)alkenylene linked to the nitrogen atom of the group Qa.Aa.N- , either of which linking groups may optionally bear a (1-4C)alkyl, phenyl or phenyl(1-4C)alkyl substituent and either of which linking groups thereby completes a ring including two adjacent carbon atoms of Q, the atoms of A and the nitrogen of group -Aa.N- ; Rd is hydrogen; Re and Rf are independently selected from hydrogen and (1-4C)alkyl, or together form (3-6C)alkylene; Qa is phenyl or pyridyl; Aa is a direct bond to the group -NRc- ; Y is a physiologically acceptable anion; and wherein any one or more of said phenyl moieties may optionally be unsubstituted or bear one or more substituents independently selected from halogeno, trifluoromethyl, cyano, nitro, (1-4C)alkyl and (1-4C)alkoxy.

Specific values for Ra, Rb, Rc, Rd, Re, Rf, Aa and Qa include, for example, the relevant values mentioned hereinabove for R¹, R², R⁴, R⁵, R⁶, Q and A.

A preferred value for R¹ or Ra is, for example, methyl, ethyl, butyl, phenyl or cyclohexyl, of which methyl is especially preferred.

A preferred value for R⁴ or Rc is, for example, methyl or ethyl, of which ethyl is especially preferred.

A yet further group of compounds of the invention of particular interest comprises compounds of the formula II wherein Qa is phenyl; Aa is a direct bond to the group -N(Rc)- ; Ra is (1-7C)alkyl or (3-6C)alkenyl; Rb is (1-4C)alkyl (such as methyl or ethyl); Rc is hydrogen, (1-6C)alkyl (such as methyl, ethyl, propyl or pentyl), (3-6C)cycloalkylmethyl (such as cyclopropylmethyl), or (3-6C)alkenyl (such as allyl or but-2-enyl); or Rc is (2-4C)alkylene

- 7 -

(such as ethylene or trimethylene) or (2-4C)alkenylene (such as vinylene or 1,3-propenylene) completing a ring including two adjacent carbon atoms of benzene ring Qa and the nitrogen atom of the group -N(Rc)- ; Rd is hydrogen or (1-4C)alkyl (such as methyl or ethyl); Re and Rf are independently selected from hydrogen and (1-4C)alkyl (such as methyl or ethyl); Y is a physiologically acceptable anion; and wherein benzene ring Qa may optionally be unsubstituted or bear one or two substituents independently selected from halogeno (such as fluoro, chloro or bromo), (1-4C)alkyl (such as methyl) and (1-4C)alkoxy (such as methoxy).

A still further group of compounds of the invention of special interest comprises compounds of the formula II wherein Qa is phenyl; Aa is a direct bond to the group -N(Rc)- ; Ra is methyl or ethyl; Rb is methyl, ethyl or propyl; Rc is ethyl; or Rc is ethylene or vinylene completing an indoline or indole ring, respectively, including two adjacent carbon atoms of benzene ring Qa and the nitrogen atom of the group -N(Rc)- ; Rd is hydrogen or methyl; Re is hydrogen and Rf is methyl or ethyl; Y is a physiologically acceptable anion; and wherein benzene ring Qa may optionally be unsubstituted or bear one or two substituents independently selected from halogeno (such as fluoro, chloro or bromo), (1-4C)alkyl (such as methyl) and (1-4C)alkoxy (such as methoxy).

Particular physiologically acceptable counter anions Y include, for example, halide (such as chloride, bromide or iodide), sulphate, fluoroborate, phosphate, nitrate, acetate, benzoate, butyrate, citrate, tartrate, dibenzoyltartrate, fumarate, trifluoroacetate, methosulphate and p-toluenesulphonate.

A preferred group of non-ionic anhydro-bases of the invention defined above comprises a compound of the formula IIa in which Ra, Rb, Rc, Rd, Aa and Qa have any of the meanings defined above and alk stands for (1-4C)alkyl (especially methyl or ethyl).

Compounds of the invention which are of particular interest include the compounds described in the accompanying Examples of which, the compounds described in Examples 20, 51, 56, 145, 147-149, 151, 156 and 158 are of special interest. The latter compounds, as described herein (or, except in the case of the non-ionic anhydro-base form described in the first part of Example 56, in the form of an

alternative physiologically acceptable counter anion), are provided as a further feature of the invention.

The compounds of the invention may be obtained by standard procedures of organic chemistry already known to be applicable to the preparation of structurally analogous compounds, for example those procedures described in standard reference works on the chemistry of the pyrimidines. Such procedures for the manufacture of the novel compounds of formula I are provided as a further feature of the invention and are illustrated by the following preferred processes in which the various generic radicals have any of the meanings defined hereinbefore:-

- a) An amino compound of the formula III is reacted with an alkylating agent of the formula $R^1.Z$ in which Z is a suitable leaving group.

A preferred value of Z is, for example, halide (especially iodide, bromide or chloride), sulphate and p-toluenesulphate.

The reaction is generally carried out by heating the alkylating agent with the compound of formula III at a temperature of, for example, 40-120 °C and is conveniently carried out in a suitable solvent or diluent, for example, in an ether such as dioxane, tetrahydrofuran or t-butyl methyl ether.

The starting materials of formula III can be made, for example, by reaction of the corresponding halogeno pyrimidine of the formula IV wherein X is chloro or bromo with the appropriate amine of the formula $Q.A.N(R^4)H$ at a temperature in the range, for example, 40-150°C. this particular reaction may be carried out in the presence of a suitable solvent or diluent such as a (1-4C)alcohol or N,N-dimethylformamide, or as a melt of the reagents alone. The amines of the formula $Q.A.N(R^4)H$ and the compounds of formula IV are in general known or may be made by conventional techniques well known in the art of organic and pyrimidine chemistry.

Although it will be appreciated that in principle it is possible for alkylation to occur on either of the endocyclic nitrogen atoms, in general alkylation takes place predominantly on the nitrogen shown bearing R^1 in formula I and any small amount of the alternative isomer may be removed by well known methods for the purification of

organic compounds, for example by chromatographic means or by fractional crystallisation. The principle exception to this is, those compounds of formula III in which R^6 is a tertiary amino group and R^2 is other than alkylamino, which compounds alkylate under the conditions of process (a) predominantly on the nitrogen atom numbered N(3) and for which values of R^2 and R^6 , the corresponding compounds of formula I are best prepared by process (b) or (c) hereinafter. The position of alkylation can be established by standard techniques, for example by studies of the nuclear Overhauser effect on the proton magnetic resonance of the sample concerned.

b) A pyrimidinium salt of the formula V wherein X is a suitable leaving group is reacted with an amine of the formula $Q.A.N(R^4)_3$.

The process will be seen to be analogous to that described above for the production of the starting materials of the formula IV and analogous conditions may in general be used. Thus, the process is generally carried out at an elevated temperature in the range, for example, 20-150 °C and in the presence of a suitable solvent or diluent such as a (1-4C)alkanol or N,N-dimethylformamide.

A particularly suitable leaving group X is, for example, halogeno (especially chloro or bromo), dichlorophosphinoyl $[-O.PO.Cl_2]$, or dibromophosphinoyl $[-O.PO.Br_2]$. The latter two groups may conveniently be introduced in situ by the reaction of the corresponding pyrimidinone with phosphorus oxychloride or oxybromide, respectively, for example as described in the accompanying Examples. [Note: it will readily be appreciated by those skilled in the art that the precise identity of the group X is not generally critical to the process (b)].

The pyrimidinium salts of formula V may alternatively be obtained, for example, by analogy with process (a) above, that is by reaction of a halogeno pyrimidine of the formula IV with the appropriate alkylating agent of the formula $R^1.Z$ and in particular an iodide or bromide of the formula $R^1.I$ or $R^1.Br$. The pyrimidinones may themselves be obtained by standard procedures, for example when R^1

- 10 -

is phenyl and the like, as described in connection with Examples 1-8 hereinafter.

c) For those compounds wherein R^6 is amino, alkylamino or dialkylamino as defined above, a pyrimidinium salt of the formula VI wherein X is a suitable leaving group is reacted with the appropriate amine selected from ammonia, (1-6C)alkylamine, dialkylamine of up to 6 carbon atoms, pyrrolidine, piperidine and morpholine, or a salt thereof with a (1-4C)alkanoic acid (such as acetic acid).

The process will be seen to be analogous to process (b) described above and analogous considerations and reaction conditions may in general be used. In general an excess of the starting amine or an alkanoic acid salt thereof will be used. The starting compounds of formula VI may be obtained in a generally similar manner to those for the formula V compounds.

It will be appreciated that the counter anion Y^- in the formula I compounds may readily be changed, for example, by reaction of the formula I compound with a suitable salt such as a silver salt or by ion-exchange chromatography on a column of a basic macroreticular resin in the form of its salt with the desired counter anion, or another conventional method. When the non-ionic anhydro-base form of a compound of I is required, (for example a compound of formula Ia, Ib or IIa), it may be obtained, for example, by reaction of the appropriate compound of formula I in which one of R^2 and R^6 is alkylamino, with a macroreticular resin containing quaternary ammonium hydroxide groups. The process is conveniently carried out by exposing a solution of the compound of formula I in an aqueous solvent such as an aqueous (1-4C)alkanol (for example methanol, ethanol or 2-propanol) to the resin at or near ambient temperature, for example by trickling the solution over a bed or through a column of the resin. The anhydro-base form may then conveniently be returned to an ionic form of formula I by reaction with the appropriate acid of formula H.Y.

It will also be appreciated that certain of the various optional substituents in the compounds of the invention may be introduced by standard aromatic substitution reactions or generated by

conventional functional group modifications either prior to or immediately following process (a), (b) or (c) above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of nitro or halogeno, reductive alkylation of nitro, oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl and reduction of alkynyl or alkenyl. The reagents and reaction conditions for such procedures are well known in the chemical art.

As indicated above, the compounds of the invention possess useful pharmacological properties and modulate the action of the sino-atrial node in warm-blooded animals in a beneficial, selective and medically useful manner so that the agents are useful in treating cardiovascular disorders associated with an inappropriately elevated heart rate and with minimal effects on other haemodynamic parameters such as blood pressure or cardiac output. The beneficial and selective effects of the cardiovascular system may be demonstrated using one or more of the following standard laboratory techniques.

a) **Bradycardic effect (reduction in beating rate of the spontaneously beating isolated guinea pig right atrium).**

This technique involves the dissection of the right atrium from a guinea pig heart, taking care not to damage the sino-atrial node region. The atrium is established in oxygenated (95% O₂; 5% CO₂) Tyrode's solution [containing 8.0g NaCl, 0.19g KCl, 0.025g MgCl₂, 0.05g NaH₂PO₄, 1.0g NaHCO₃, 0.2g CaCl₂ and 2.7g glucose, per litre of deionised water] between two platinum spikes which are connected via an amplifier to a conventional rate-meter, triggered by the action potentials across the atrium. The preparation is bathed in oxygenated Tyrode's solution at 37 degrees Celsius and allowed to equilibrate for 30 minutes before the addition of a solution of the test compound in a mixture of dimethyl sulphoxide and Cremophor EL, diluted as required with Tyrode's solution. Further solutions of test compound are then added cumulatively at 15 minute intervals or when a steady-state beating rate has been attained. This enables an IC₂₀ (i.e. the micromolar concentration required to reduce the beating rate by 20%) to be calculated. Typically, a compound of formula I will have an IC₂₀ of 10 micromolar or less.

b) Effect on contractile force of electrically stimulated isolated guinea pig left atrium.

This technique involves the dissection of the left atrium from a guinea pig heart into oxygenated Tyrode's solution. The atrium is then clamped in a polyacrylate plastic holder containing two stainless steel stimulating electrodes. The free end of the atrium (normally the atrial appendage) is attached with silk thread to an isometric force transducer. The atrium is then set under a resting tension of 1g and is allowed to equilibrate in oxygenated Tyrode's solution for 20 minutes before being stimulated into beating by application of 2.5 Hz, 3 mS pulses at 1.5 times the threshold voltage (normally in the range 3-7 V). A solution (10^{-5} M or less) of the test compound [made up essentially as in (a) above, but using physiological saline solution in place of Tyrode's solution] is then added and the effect on contractile force measured. In this way a comparison of the effect with that of a control solution without any test compound can be obtained. Typically, at a concentration in the range 1-30 micromolar compounds of the formula I show <15% reduction in contractile force.

c) Bradycardic effect in the anaesthetised rat

This technique involves the use of Wistar rats (Alderley Park strain) which are pre-anaesthetised by intravenous injection of alphaxalone/ alphadalone (1.5ml per kg). A polyethylene cannula is inserted into the jugular vein and anaesthesia is maintained by infusion of alphaxalone/alphadalone at a rate of 0.025-0.12 ml per kg per minute. A polyethylene cannula is also inserted into the carotid artery and connected to a pressure transducer filled with physiological saline solution. The arterial blood pressure signal is used to trigger an internally calibrated heart rate meter and the transducer is calibrated with a mercury manometer. The output of the heart rate meter and of the pressure transducer are then recorded simultaneously on a standard chart recorder. After cannulation, the rat preparation is allowed to stabilise for 10 minutes. A solution of a test compound [made up as in (a) above, in a volume of 1ml per kg] is then administered via the venous cannula in four cumulative doses separated by 5 minute intervals. A group of five rats is used for

- 13 -

each test compound. The effects on heart rate and blood pressure may then be determined in comparison with those of a control injection. Typically, a compound of formula I active using this procedure will require an i.v. dose of 5 mg/kg or less to produce a 30% reduction in heart rate (i.e. the ED₃₀ dose).

The beneficial effects of a test compound on the cardiovascular system, such as bradycardic effects without an adverse effect on heart force, blood pressure and or cardiac output, may also be determined in anaesthetised dogs and in dogs in which tachycardia has been induced by exercise. In general, the compounds of the invention show significant and predominantly selective bradycardic effects as evidenced by activity in at least two of the above mentioned test techniques. No overt toxicity is generally observed with the compounds of formula I in the above in vivo test techniques at doses several multiples of those at which significant bradycardic effects are seen.

By way of illustration, the compound described hereinafter in Example 51 had an IC₂₀ of about 10⁻⁶ M in procedure (a) and had an ED₃₀ of 0.3 mg/kg i.v. for reduction of heart rate in procedure (c). Other compounds of formula I exemplified hereinafter will in general show activity of the same general order.

When used in the treatment of diseases of the cardiovascular system, such as myocardial ischaemia affecting warm-blooded animals (and in particular man), it is envisaged that a compound of formula I will be administered orally, intravenously or by some other medically acceptable route (such as by inhalation, insufflation, sub-lingual or transdermal means) so that a dose in the general range, for example, 0.01 mg to 10 mg per kg body weight is received. However, it will be understood that the precise dose administered will necessarily vary according to the nature and severity of the disease and the age and sex of the patient being treated.

In general, the pyrimidinium salts of formula I (or the related non-ionic anhydro-bases) will usually be administered in the form of a pharmaceutical composition, that is, together with a pharmaceutically acceptable diluent or carrier and such a composition is provided as a further feature of the invention. It will be recognised that it may be convenient to produce a particular

pyridinium salt of formula I in situ, by using the appropriate anhydro-base and incorporating an acid of the formula HX during the production of a particular formulation.

A composition of the invention may be in a variety of dosage forms. For example, it may be in the form of tablets, capsules, solutions or suspensions for oral administration; in the form of a suppository for rectal administration; in the form of a sterile solution or suspension for administration by intravenous or intramuscular injection; in the form of an aerosol or a nebuliser solution or suspension, for administration by inhalation; in the form of a powder, together with pharmaceutically acceptable inert solid diluents such as lactose, for administration by insufflation; or in the form of a skin patch for transdermal administration. The compositions may conveniently be in unit dose form containing, for example, 5 - 200 mg of the compound of formula I.

A composition may be obtained by conventional procedures using pharmaceutically acceptable diluents and carriers well known in the art. Tablets and capsules for oral administration may conveniently be formed with a coating, such as an enteric coating (for example, one based on cellulose acetate phthalate) to minimise dissolution of the active ingredient of formula I in the stomach or to mask unpleasant taste.

The compositions of the invention may also contain one or more agents known to be of value in the diseases or conditions of the cardiovascular system intended to be treated. Thus, they may contain, in addition to the compound of formula I, for example, one or more other known agents selected from platelet aggregation inhibitors, prostanoid constrictor antagonists or synthase inhibitors (such as thromboxane A_2 antagonists or synthase inhibitors), cyclooxygenase inhibitors, hypolipidemic agents, anti-hypertensive agents (such as an angiotensin converting enzyme inhibitors, renin inhibitors or angiotensin antagonists), inotropic agents, β -adrenergic antagonists, thrombolytic agents, vasodilators and calcium channel antagonists.

In addition to their use in therapeutic medicine, the compounds of formula I are also useful as pharmacological tools in the development and standardisation of test systems for the evaluation of

the new cardiovascular agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice.

The invention will now be illustrated by the following non-limiting Examples in which, unless otherwise stated:-

- (i) evaporations were carried out by rotary evaporation in vacuo;
- (ii) operations were carried out at room temperature, that is in the range 18-26°C;
- (iii) flash column chromatography or medium pressure liquid chromatography (MPLC) was performed on silica gel [either Fluka Kieselgel 60 (catalogue no. 60738) obtained from Fluka AG, Buchs, Switzerland, or Merck Kieselgel Art. 9385, obtained from E Merck, Darmstadt, Germany];
- (iv) yields are given for illustration only and are not necessarily the maximum attainable by diligent process development;
- (v) proton NMR spectra were normally determined at 200 MHz in deuterated dimethyl sulphoxide as solvent, using tetramethylsilane (TMS) as an internal standard, and are expressed as chemical shifts (delta values) in parts per million relative to TMS using conventional abbreviations for designation of major peaks: s, singlet; m, multiplet; t, triplet; br, broad; d, doublet;
- (vi) all end-products were characterised by microanalysis, NMR and/or mass spectroscopy; and
- (vii) conventional abbreviations are used for individual radicals and recrystallisation solvents, for example, Me = methyl, Et = ethyl, Pr = Propyl, Prⁱ = isopropyl, Bu = butyl, Buⁱ = isobutyl, Ph = phenyl; EtOAc = ethyl acetate, Et₂O = ether, MeCN = acetonitrile, MeOH = methanol, EtOH = ethanol, PrⁱOH = 2-propanol, H₂O = water.

Example 1

A mixture of 1,4-dihydro-1-heptyl-6-methyl-2-methylamino-4-pyrimidinone monohydrate (0.75 g, 2.9 mM) and phosphorus oxychloride (3.5 ml, an excess) was heated at a bath temperature of 130°C for 2.5 hours. Excess phosphorus oxychloride was removed by evaporation. The residue was mixed with toluene (20ml) and the volatile material evaporated. The procedure was repeated with a further portion of toluene (20ml) to give 4-chloro-1-heptyl-6-methyl-2-methylamino-pyrimidinium chloride as a crude solid. This material was mixed with ethanol (5ml) and N-methylaniline (0.8 g, 7.5mM). The solution obtained was heated at reflux for 2.5 hours. The ethanol was removed by evaporation and water (10 ml) was added to the residue. The aqueous mixture was extracted with ether (4 x 10 ml) and the extracts were discarded. The aqueous phase was extracted with methylene chloride (4 x 10 ml). Water was removed from these extracts by filtration through phase-separating filter paper and the solvent was evaporated. The brown, oily residue obtained crystallised on trituration with ether to give a white solid (0.742 g). This solid was recrystallised from acetone-ether to give 1-heptyl-6-methyl-2-methylamino-4-N-methylanilinopyrimidinium chloride as a crystalline solid (0.49 g, 46% yield), m.p. 154-155°C; microanalysis, found: C,65.7; H,8.6; N,14.9%; $C_{20}H_{31}N_4Cl \cdot 0.25 H_2O$ requires C,65.3; H,8.6; N,15.2%; NMR: 0.9(3H,t,CH₃), 1.3[10H,complex,(CH₂)₅], 2.36(3H,s,CH₃), 2.9(3H,br,NCH₃), 3.5(3H,s,N-CH₃), 4.0(2H,t,NCH₂), 5.8(1H,br,aromatic), 7.4-7.6(5H,complex,aromatic), 8.65(1H,br,NH).

Example 2

The procedure described in Example 1 was repeated using N-ethylaniline. There was thus obtained 4-N-ethylanilino-1-heptyl-6-methyl-2-methylaminopyrimidinium chloride (0.527 g, 48% yield), m.p. 126-128°C; microanalysis, found: C,66.7; H,9.0; N,14.5%; $C_{21}H_{33}N_4Cl$ requires C,66.9; H,8.8; N,14.9%; NMR: 0.87(3H,t,CH₃), 1.2(3H,t,CH₃), 1.26[10H,complex,(CH₂)₅], 2.3(3H,s,CH₃), 3.0(3H,br, NCH₃), 4.0(4H,complex,NCH₂), 5.6(1H,br,aromatic), 7.3-7.6(5H,complex,aromatic).

The pyrimidinone starting material for Examples 1 and 2 was prepared as follows:-

(i) A solution of heptylamine (9.66 g, 84 mM) in methylene chloride (30 ml) was added dropwise to a stirred suspension of 2H-3,4-dihydro-6-methyl-2-thioxo-1,3-oxazin-4-one (6 g, 42 mM) in methylene chloride (120 ml). The resulting solution was left at ambient temperature for 16 hours and the solvent removed by evaporation. A mixture of the residue in acetic acid (20 ml) was heated under reflux for 30 minutes. The solvent was removed by evaporation and the residue purified by flash column chromatography on Fluka Kieselgel 60 using ether as eluant to give 2,3-dihydro-1-heptyl-6-methyl-2-thioxo-4(1H)-pyrimidinone as a solid having a satisfactory microanalysis.

(ii) The thioxo compound (2.42 g, 1.01mM) from (i) above in acetonitrile (30 ml) and methyl iodide (4 ml, an excess) was heated under reflux for 8 hours. The solvent was removed by evaporation and the residue was shaken with a mixture of methylene chloride (20 ml) and saturated aqueous sodium carbonate solution (30 ml). The organic layer was washed with water (20 ml) and water removed by filtration through phase-separating filter paper. Removal of the solvent by evaporation gave an oily residue, which slowly solidified to give 1,4-dihydro-1-heptyl-6-methyl-2-methylthio-4-pyrimidinone (2.2 g) as a solid which was used without further purification.

(iii) Methylammonium acetate (14 g, an excess) was added to the methylthio compound (2.2 g) from (ii) above. The mixture was heated at a bath temperature of 175-180°C for 0.5 hours and allowed to cool. Water (10 ml) was added and the oily mixture was extracted with methylene chloride (4 x 10 ml). Water was removed from the extracts by filtration through phase-separating filter paper. Evaporation of the solvent left a residue, which was treated with water (10 ml). The crystalline solid which was precipitated was collected by filtration, washed with water, and recrystallised from ethyl acetate to give 1,4-dihydro-1-heptyl-6-methyl-2-methylamino-4-pyrimidinone monohydrate (1.68 g, 65% yield), m.p. 100-103°C; microanalysis, found: C, 61.5; H, 9.8; N, 16.7%; $C_{13}H_{22}N_3O \cdot H_2O$ requires: C, 61.4; H, 9.4; N, 16.5%.

Examples 3-8

The procedure described in example 1 was repeated using the appropriate 4-chloro-1-substituted-pyrimidine derivative of the formula V (X = Cl) [obtained in situ from the corresponding 4-pyrimidinone] and the appropriate aniline. There were thus obtained the following compounds of the formula I ($R^5=H$, $R^6=CH_3$, A=direct bond, Q=phenyl, $Y=Cl^-$):-

Hydration	Example	R^1	R^2	R^4	m.p. °C	yield (%) (recryst. solvent)
---	3	cyclo- hexyl	NH ₂	Et	219-220	34 (Me ₂ CO/Et ₂ O)
0.25 H ₂ O	4	phenyl	NHMe	Me	227-228	37 (Me ₂ CO)
1.0 H ₂ O	5	phenyl	NHMe	Et	128-129	15 (EtOAc)
1.33 H ₂ O	6	phenyl	NH ₂	Me	125-127	8 (Me ₂ CO/Et ₂ O)
0.25 H ₂ O	7	4-MeO- phenyl	NH ₂	Et	215-216	46 (Me ₂ CO/Et ₂ O)
0.75 H ₂ O	8	phenyl	NH ₂	Et	249-250	11 (EtOAc)/Et ₂ O

The starting material for Example 3 was prepared as follows:-

- (i) Cyclohexylthiourea (27.8 g, 176 mM) and 2,6,6-trimethyl-1,3-dioxin-4-one (90%, 36 ml, 229 mM) were heated with a bath temperature of 120°C for 2 hours. The mixture was allowed to cool and was triturated with ether. The solid obtained was purified by filtration chromatography on silica (Fluka Kieselgel 60) using methylene chloride/pentane (1:1) as eluant. The material obtained was purified by further chromatography on silica (Kieselgel 60) using ethyl acetate/pentane (1:4) as eluent. There was thus obtained 1-cyclohexyl-3-(3-oxobutanoyl)thiourea (17.7 g, 42%) as a solid, m.p. 100-102°C: m/e: 242(M⁺).

(ii) A mixture of the above thiourea (10.7 g, 44 mM) and p-toluenesulphonic acid (10.7 g, 56 mM) was heated in refluxing ethanol (80 ml) for 18 hours. The solution was cooled to 5°C. The resulting crystalline precipitate was collected by filtration to give 1-cyclohexyl-2,3-dihydro-6-methyl-2-thioxo-4(1H)-pyrimidinone (3.6 g, 36%), m.p. 240-243°C; microanalysis, found: C, 59.1; H, 7.3; N, 12.4%; $C_{11}H_{16}N_2OS$ requires: C, 58.9; H, 7.1; N, 12.5%.

(iii) A mixture of the above thioxo compound (2.96 g, 13.2 mM) and methyl iodide (8.8 mL, an excess) was heated under reflux in acetonitrile (10 ml) for 5 hours. The solvent was removed by evaporation and the residue was shaken with a mixture of saturated aqueous sodium carbonate (50 ml) and ethyl acetate (50 ml). The aqueous phase was further extracted with ethyl acetate (3 x 50 ml). The combined extracts were dried ($MgSO_4$) and solvent removed by evaporation to give 1-cyclohexyl-1,4-dihydro-6-methyl-2-methylthio-4-pyrimidinone as a crude solid (3.1 g) which was used without further purification. [A sample from a repeat preparation was recrystallised from ethyl acetate/ petroleum ether (b.p. 60-80°C.) to give solid of m.p. 184-186°C and microanalysis, found: C, 60.5; H, 7.9; N, 11.8%; $C_{12}H_{18}H_2OS$ requires: C, 60.5; H, 7.6; N, 11.8%.]

(iv) A mixture of the above methylthio compound (3.1 g) and ammonium acetate (15 g) was heated at 180°C (bath temperature) for 2 hours. Further portions (5g) of ammonium acetate were added at intervals of 20 minutes. The mixture was then cooled and water (50 ml) was added. The aqueous mixture was extracted with methylene chloride (8 x 50 ml) and the combined organic extracts were dried ($MgSO_4$) and the solvent evaporated. The semi-solid residue was dissolved in ethanol (50 ml) and concentrated aqueous sodium hydroxide solution (5 ml). The volatile material was removed by evaporation. The residue was treated with ethanol (50 ml), followed by 2M hydrochloric acid to pH<3. The solvents were then removed from the acid mixture. The solid residue was extracted with hot methanol and the extracts clarified by filtration. The filtrate was evaporated and the residue was recrystallised first from ethanol/2-propanol (1:1v/v) and then from ethanol. There was thus obtained 2-amino-1-cyclohexyl-1,4-dihydro-6-methyl-4-pyrimidinone hydrochloride (0.98 g, 30% based on thioxo compound), m.p. 225-226°C, with a satisfactory microanalysis.

The starting material for Ex. 7 was prepared as follows:-

N-(4-Methoxyphenyl)thiourea (18.2 g, 100 mM) and 2,6,6-trimethyl-1,3-dioxin-4-one (21.3 g, 150 mM) were heated together at 140°C (bath temperature) for 30 minutes. The solid product was cooled, treated with ethanol (100 ml), boiled for 10 minutes, cooled and the solid product was isolated by filtration. More dioxinone (21.3 g) was added to the above material and the mixture was heated at 140°C for a further 20 minutes. Ethanol (50 ml) was then added to the cooled mixture, which was then heated under reflux for 5 minutes. The mixture was cooled and the solid product isolated by filtration to give 2,3-dihydro-1-(4-methoxyphenyl)-6-methyl-2-thioxo-4(1H)-pyrimidinone (17.9 g, 72% yield) m.p. 248-249°C; microanalysis, found: C, 58.2; H, 4.9; N, 11.0%; $C_{12}H_{12}N_2OS$ requires: C, 58.1; H, 4.8; N, 11.3%.

The methylthio pyrimidinones necessary for the preparation of Examples 4-8 were obtained in an analogous manner to that described for the equivalent starting material for Example 3:-

- (1) 1,4-dihydro-6-methyl-2-methylthio-1-phenyl-4-pyrimidinone (required for Examples 4-6 and 8): obtained as a solid in 67% yield, m.p. 225°C (dec.) after trituration with acetone; and
- (2) 1,4-dihydro-6-methyl-1-(4-methoxyphenyl)-2-methylthio-4-pyrimidinone (required for Example 7): obtained as a solid in 73% yield, m.p. 211-213°C after recrystallisation from acetonitrile.

The necessary aminopyrimidinones were obtained in an analogous manner to that described for the equivalent starting material for Example 3:-

- (3) 1,4-dihydro-6-methyl-2-methylamino-1-phenyl-4-pyrimidinone hydrochloride (required for Examples 4 and 5): obtained as a solid, m.p. 199-200°C in 90% yield, after purification by flash column chromatography on silica (Kieselgel 60) using methylene chloride/methanol (9:1v/v) as eluant;
- (4) 2-amino-1,4-dihydro-6-methyl-1-phenyl-4-pyrimidinone acetate (required for Examples 6 and 8): obtained as a solid, m.p. 269-271°C in 42% yield, after recrystallisation from ether/acetic acid; and

(5) 2-amino-1,4-dihydro-1-(4-methoxyphenyl)-6-methyl-4-pyrimidinone hydrochloride (required for Example 7): obtained as a solid, m.p. 287-289°C in 56% yield, after recrystallisation from ethanol.

Example 9

A mixture of 2-amino-4-N-ethylanilinopyrimidine (2.2 mM), allyl bromide (6.5 mM) and dioxan (1 ml) was heated at 100°C for 1.5 hours. The precipitated solid was collected by filtration, washed with dioxan and ether and then dried. There was thus obtained 1-allyl-2-amino-4-N-ethylanilinopyrimidinium iodide in 60% yield, m.p. 174-176°C; having a satisfactory microanalysis and NMR spectrum.

[Note: the site of quaternisation was confirmed by conventional Nuclear Overhauser studies]

The pyrimidine starting material was prepared as follows:-

A mixture of 4-chloro-2-aminopyrimidine (4.63 mM) and N-aniline (1.0 ml, 9.2 mM) was heated as a melt at 95-100°C for 15 hours. The residue was partitioned between methylene chloride (50 ml) and 2M hydrochloric acid (50 ml) and stirred for 15 minutes. The organic phase was separated and the aqueous phase was extracted again with further portions of methylene chloride (2x20 ml). The combined organic layers were washed successively with saturated sodium bicarbonate solution, water and brine (50 ml each), dried (MgSO₄) and then the solvent was evaporated. The residual solid was triturated with ether and hexane and separated by filtration to give 2-amino-4-N-ethylanilinopyrimidine in 17% yield, m.p. 188-190 °C.

Examples 10-12

The procedure described in Example 9 was repeated, but using the appropriate substituted pyrimidine of formula III and appropriate alkylating agent of formula R¹. Y heated together for about 18 hours. The following compounds of formula I (Q=phenyl, A=direct bond, R⁵=R⁶=H) were obtained, all of which were recrystallised from methanol and ether:-

Example	R ²	R ¹	R ⁴	Y	m.p. (°C)	yield (%)
10	NH ₂	Pr ^c .CH ₂	Et	Br	215-216	57
11	NH ₂	benzyl	Et	Cl	254-256	65*
12	NH ₂	allyl	Pr	Br	175-177	39

Notes: (1) * obtained as a partial hydrate (0.25 H₂O).

(2) Pr^c.CH₂ stands for cyclopropylmethyl.

The necessary starting 2-amino-4-N-propylanilinopyrimidine for Example 12 was made in an analogous manner to that described for the analogous intermediate in Example 9 and was obtained as a solid, m.p. 82-84°C in 89% yield.

Example 13

A solution of 2-amino-4-(indolin-1-yl)pyrimidine (212 mg; 1 mM) in warm N,N-dimethylformamide (DMF, 15 ml) was treated with ethyl iodide (1ml). The mixture was allowed to stand at ambient temperature for 15 hours and the precipitated solid was filtered and washed with ethyl acetate. There was thus obtained 1-ethyl-2-amino-4-(indolin-1-yl)pyrimidinium iodide (280 mg, 79%), m.p. >310°C; microanalysis, found: C, 44.2; H, 4.8; N, 15.1%; C₁₄H₁₇N₄I.0.5H₂O requires: C, 44.6; H, 4.8; N, 14.9%; NMR: 1.2-1.4 (3H, t, CH₂CH₃), 3-2-3.4 (2H, t, indoline-3CH₂), 3.95-4.1 (2H, q, CH₂CH₃), 4.1-4.3 (2H, t, indoline-2CH₂), 6.55-6.65 (1H, d, pyrimidine-5H), 7.1-7.4 (3H, complex, aromatic), 8.1-8.2 (1H, d, indoline-7H), 8.25-8.5 (2H, br, NH₂), 8.63-8.73 (1H, d, pyrimidine-6H).

The starting material was prepared as follows:-

A suspension of 2-amino-4-chloropyrimidine (1.3 g; 10 mM) in dioxan (30ml) was treated with indoline (2.4g; 20mM) and the mixture was heated for 18 hours at 95-100°C. The precipitated product was separated from the cooled mixture by filtration and suspended in a mixture of 2-propanol (30ml) and a solution of potassium hydroxide

flake (6g) in water (10ml). This mixture was stirred and heated at 95-100°C for one hour. The hot 2-propanol solution was separated from the aqueous layer and allowed to cool. The solid product was recrystallised from 2-propanol to give 2-amino-4-(indolin-1-yl)-pyrimidine as a solid (1.9g, 89.6%), m.p. 177-179°C; microanalysis, found: C, 62.2; H, 6.2; N, 23.8%; $C_{12}H_{12}N_4 \cdot H_2O$ requires: C, 62.6; H, 6.1; N, 24.3%.

Examples 14-15

The procedure described in Example 13 was repeated using propyl or heptyl iodide. There were thus obtained the following compounds:-

(Example 14): 2-amino-4-(indolin-1-yl)-1-propylpyrimidinium iodide, as a solid, m.p. >310°C, in 42% yield; and

(Example 15): 2-amino-4-(indolin-1-yl)-1-heptylpyrimidinium iodide, as a solid, m.p. 219-221°C, in 57% yield.

Example 16

A mixture of 2-amino-4-(indol-1-yl)pyrimidine (210 mg, 1 mM) and methyl iodide (1 ml) in dioxan (5 ml) was heated for 2 hours at 95-100°C. The mixture was cooled and the precipitated product was collected by filtration, washed with ethyl acetate and then crystallised from methanol. There was thus obtained 2-amino-4-(indol-1-yl)-1-methyl-pyrimidinium iodide (280 mg; 79.5%) m.p. 295-296°C (decomp.), microanalysis, found: C, 44.3; H, 3.6; N, 15.5%; $C_{13}H_{13}N_4I$ requires: C, 44.3; H, 3.7; N, 15.9%; NMR: 3.71(3H, s, N-CH₃), 6.95-7.05 (1H, d, indole-3H), 7.3-7.45(3H, complex aromatic), 7.45-7.55 (1H, d, pyrimidine-5H) 7.65-7.75(1H, complex, indole-7H), 8.15-8.25 (1H, d, indole-2H), 8.45-8.55(1H, d, pyrimidine-6H), 8.8-9.5(2H, br, NH₂).

The indole starting material was prepared as follows:-

A mixture of 2-amino-4-(indolin-1-yl)pyrimidine (2.6 g, 12 mM) and 30% w/w palladium on charcoal (260 mg) in diphenyl ether (15 ml) was heated under reflux for 2 hours. The mixture was cooled, diluted with methylene chloride (100 ml) and filtered through diatomaceous earth. The filtrate was concentrated in vacuo and the residual oil was diluted with hexane (200 ml). The precipitated solid was collected by filtration and washed with hexane. There was thus

obtained 2-amino-4-(indol-1-yl)-pyrimidine (2.1 g; 81.5%), m.p. 163-165°C; microanalysis, found: C, 68.5; H, 4.6; N, 26.2%; $C_{12}H_{10}N_4$ requires: C, 68.6; H, 4.8; N, 26.7%.

Examples 17-19

The procedure described in Example 16 was repeated using ethyl, propyl or pentyl iodide as alkylating agent for 18 hours instead of 2 hours. there were thus obtained the following compounds of formula I:-

(Example 17): 2-amino-1-ethyl-4-(indol-1-yl)pyrimidinium iodide, as a solid, m.p. 248-250°C (with decomposition), after recrystallisation from methanol and in 59% yield;

(Example 18): 2-amino-4-(indol-1-yl)-1-propylpyrimidinium iodide, as a solid, m.p. 256-258°C (with decomposition), after recrystallisation from methanol/ether and in 32% yield; and

(Example 19): 2-amino-4-(indol-1-yl)-1-pentylpyrimidinium iodide as a solid, (isolated as a methanolate), m.p. 134-136°C, after recrystallisation from methanol/ether and in 25% yield.

Example 20

A mixture of 6-methyl-2-methylamino-4-N-methylanilino-pyrimidine (14.01, 61.5 mM), methyl iodide (10.7 ml, 172 mM) and dioxan (140 ml) was heated at reflux for 15 hours. The mixture was cooled. The solid was collected by filtration, washed with dioxan (10 ml) and hexane (100 ml) and then recrystallised from 2-propanol. There was thus obtained 1,6-dimethyl-2-methylamino-4-N-methylanilino-pyrimidinium iodide (15.38 g, 67.6% yield) m.p. 212- 213°C, microanalysis, found: C, 45.6; H, 5.1; N, 15.4%; $C_{14}H_{19}NI$ requires: C, 45.52; H, 5.17; N, 15.13%; NMR: 2.2-2.4(3H, s, CH_3), 2.85-3.15 (3H, br, $NHCH_3$), 3.4(3H, s, N_4-CH_3), 3.5-(3H, s, $N-CH_3$), 5.7-5.85 (1H, br, pyrimidine 5-H), 7.35-7.6(5H, complex. aromatic), 8.1-8.25(1H, br, NH).

[Note: the site of quaternisation was confirmed by conventional Nuclear Overhauser studies].

The pyrimidine starting material was prepared as follows:-

A mixture of 4-chloro-6-methyl-2-methylaminopyrimidine (21.0 g, 133 mM; described in UK Patent Specification Ser. No. 152327) and *N*-methylaniline (15.69 g, 147 mM) was heated as a melt at 95-100°C for 15 hours. The residue was partitioned between methylene chloride (200 mL) and 2*M* hydrochloric acid (200 ml) and then stirred for 15 minutes. The organic phase was separated and the aqueous phase was extracted again with further portions of methylene chloride (2 x 25 ml). This procedure was repeated and the combined organic layers were dried (MgSO₄) and the solvent evaporated. The residual solid was recrystallised from hexane to give 6-methyl-2-methylamino-4-*N*-methylaminopyrimidine (21.8 g, 72% yield), m.p. 114-114.5°C; microanalysis, found: C, 68.2; H, 7.1; N, 24.7%; C₁₃H₁₆N₄ requires C, 68.39; H, 7.06; N, 24.54%.

Examples 21-46

The procedure described in Example 20 was repeated using the appropriate substituted pyrimidine of formula III and alkylating agent of formula R¹.Y. There were thus obtained the following compounds of formula I (R¹=R⁶=CH₃, R⁵=H; Y⁻ = iodide):-

Ex	R ²	R ⁴	Q.A	recrystallisation solvent(s)	melting point (°C)	yield (%)
21	NHCH ₃	Et	phenyl	EtOAc/EtOH	158-160	58
22	NHCH ₃	Pr	phenyl	EtOAc/Me ₂ CO	166-167	52
23	NHCH ₃	Pr ⁱ	phenyl	Me ₂ CO	217-219	59
24	NHCH ₃	allyl	phenyl	EtOAc/EtOH	152-153	50
25	NHCH ₃	Bu	phenyl	EtOAc	160.5-161.5	48
26	NHCH ₃	pentyl	phenyl	EtOAc/EtOH	160-162	51
27	NHCH ₃	H	phenyl	EtOH	292-293	55

Ex	R ²	R ⁴	O.A	recrystallisation solvent(s)	melting point (°C)	yield (%)
28	NHCH ₃	Me	4-chlorophenyl	Pr ⁱ OH	206-208	68
29	NHCH ₃	Me	4-methylphenyl	Pr ⁱ OH	205-206	44
30	NHCH ₃	allyl	2,5-dimethyl- phenyl	EtOAc/EtOH	142-145	60
31	NHCH ₃	pentyl	2,5-dimethyl- phenyl	EtOAc	177-178	43
32	NH ₂	Me	phenyl	Pr ⁱ OH	250-251.5	49
33	NH ₂	H	2-nitrophenyl	EtOH/H ₂ O	265-267	36
34	NH ₂	H	4-chlorophenyl	EtOH/H ₂ O	278-280	7
35	NH ₂	H	2-carboxy- ** phenyl	H ₂ O	185-186	38
36	NH ₂	H	3,5-dimethyl- phenyl	EtOH	265-266	46
37	NH ₂	H	3,5-dichloro- phenyl	EtOAc/EtOH	310-311*	26
38	NH ₂	H	3,5-dibromo- phenyl	EtOH	276-278	33
39	NH ₂	Me	2,5-dimethyl- phenyl	dioxan	236-237	21
40	NH ₂	Me	3,5-dimethoxy- phenyl	EtOAc/EtOH	276-277	56

Ex	R ²	R ⁴	Q.A	recrystallisation solvent(s)	melting point (°C)	yield (%)
41	NMe ₂	H	phenyl	EtOH	220-222	46
42	NMe ₂	H	2,5-dimethyl- phenyl	EtOH	230-231*	28
43	NMe ₂	H	3,5-dimethyl- phenyl	EtOH	237-238	48
44	NMe ₂	H	phenyl	Pr ⁱ OH	133-133	32

** isolated as the p-toluenesulphonate salt.

* melting point accompanied by decomposition.

(Example 45)

Similarly, 1,6-dimethyl-4-(1,2,3,4-tetrahydro-1-quinolyl-amino)-2-methylaminopyrimidinium iodide was obtained as a solid in 28% yield, m.p. 128-130°C, by reaction of 6-methyl-4-(1,2,3,4-tetrahydro-1-quinolylamino)-2-methylaminopyrimidine with methyl iodide.

The necessary starting pyrimidines of formula III (R⁶=CH₃, R⁵=H) were made in an analogous manner to that described for the starting material of Example 20 and had the following properties:-

III No.	R ²	R ⁴	Q.A	Recrystallisation Solvent(s)	Melting Point (°C)	Yield (%)
1	NHMe	Et	phenyl	hexane	125-127	62
2	NHMe	Pr	phenyl	cyclohexane	140-141	43
3	NHMe	Pr ⁱ	phenyl	EtOAc	151-152	34
4	NHMe	allyl	phenyl	---	114-116	61

III No.	R ²	R ⁴	O.A	Recrystallisation Solvent(s)	Melting Point (°C)	Yield (%)
5	NHMe	Bu	phenyl	hexane	102-104	21
6	NHMe	pentyl	phenyl	---	85-87	47
7	NHMe	H	phenyl	EtOAc	135-136	61
8	NHMe	Me	4-chlorophenyl	hexane	127-129	35
9	NHMe	Me	4-methylphenyl	hexane	128-129	49
10	NHMe	allyl	2,5-dimethyl- phenyl	Et ₂ O	95-97	53
11	NHMe	pentyl	2,5-dimethyl- phenyl	Et ₂ O/pentane	97-99	39
12	NH ₂	Me	phenyl	hexane/EtOAc	149-150	35
13	NH ₂	H	2-nitrophenyl	butanol	188-189	50
14	NH ₂	H	4-chlorophenyl	butanol	214-217	30
15	NH ₂	H	2-carboxy- phenyl	H ₂ O	303 + (decomp.)	60
16	NH ₂	H	3,5-dimethyl- phenyl	EtOAc/hexane	171-173	63
17	NH ₂	H	3,5-dichloro- phenyl	acetonitrile	175-176	61
18	NH ₂	H	3,5-dibromo- phenyl	acetonitrile	179-181	43

III No.	R ²	R ⁴	Q.A	Recrystallisation Solvent(s)	Melting Point (°C)	Yield (%)
19	NH ₂	Me	2,5-dimethyl- phenyl	ethanol	179-181*	21
20	NH ₂	H	3,5-dimethoxy- phenyl	EtOAc/hexane	149-150	31
21	NMe ₂	H	phenyl	hexane/EtOAc	134-135	35
22	NMe ₂	H	2,5-dimethyl- phenyl	pentane	110-11	48
23	NMe ₂	H	3,5-dimethyl- phenyl	hexane	80-81	34
24	NMe ₂	Me	phenyl	Et ₂ O **	166-167	78

* isolated as fumarate salt

** isolated as dibenzoyl tartrate salt

Similarly the starting material for Example 45, that is 6-methyl-4-(1,2,3,4-tetrahydro-1-quinolylamino)-2-methylaminopyrimidine, was obtained as a solid in 41% yield, m.p. 215-216°C (hydrochloride salt), by reaction of 4-chloro-6-methyl-2-methylaminopyrimidine with 1,2,3,4-tetrahydroquinoline.

Example 46

Using an analogous procedure to that described in Example 1, was repeated but starting from the known compound 1,6-dimethyl-2-methylaminopyrimidin-4-one (Agai *et alia*, Period.

Polytech. Chem. Eng., 1974, 18, 47) which was then reacted with phosphorus trichloride to produce the corresponding reactive quaternary derivative, there was obtained 1,6-dimethyl-2-methylamino-4-(N-methyl-3-phenoxypropylamino)pyrimidinium chloride, as a solid, m.p. 167-169°C (recrystallised from acetone/water) in 22% yield (partial hydrate: 0.25 H₂O).

Examples 47-49

A mixture of 2-amino-4-chloro-1,6-dimethylpyrimidinium iodide (1.43g, 5 mM), N-allylaniline (0.67 g, 5 mM), dioxan (15 ml) and N,N-dimethylformamide (15 ml) was heated at 90-100°C for 15 hours. The volatile material was removed by evaporation and the residue was crystallised from ethanol to give 4-N-allylanilino-2-amino-1,6-dimethylpyrimidinium iodide, (Example 47), (0.35 g, 15% yield), m.p. 271-272°C; microanalysis, found: C,46.8; H,5.0; N,14.9; C₁₅H₁₉N₄I requires: C,47.1; H,4.97; N,14.66; NMR (200 MHz): 2.3(3H,s,C-CH₃), 3.45(3H,s,N-CH₃), 4.5-4.6(2H,d,NCH₂), 5.1-5.25(2H, s+d, CH=CH₂), 5.65-5.8(1H, br, pyrimidine 5H), 5.8-6.0(1H,m,CH=CH₂), 7.3-7.6(5H, complex, aromatic), 8.0-8.4(2H,br,NH₂).

[Note: the starting aminochloropyrimidine may be described by Ainley *et alia* in J. Chem. Soc., 1953, 59-70].

Using a similar procedure the following compounds of formula I were obtained:-

(Example 48): 2-amino-4-N-ethylanilino-1,6-dimethylpyrimidinium iodide, as a solid in 25% yield, m.p. 231-232°C (recrystallised from 2-propanol), using N-ethylaniline instead of N-allylaniline; and

(Example 49):

2-amino-4-(p-methylthioanilino)-1,6-dimethylpyrimidinium iodide, as a solid in 51% yield, m.p. 260-262°C (recrystallised from water) using p-methylthioaniline instead of N-allylaniline.

Example 50

Using a similar procedure to that described in Example 20, 1,6-dimethyl-4-(1-indolyl)-2-methylaminopyrimidinium iodide was obtained as a solid in 33% yield, m.p. 304-305°C, by reaction of 4-(1-indolyl)-6-methyl-2-methylaminopyrimidine with methyl iodide.

The starting material was prepared as follows:-

A mixture of 4-(1-indolyl)-6-methyl-2-methylamino-pyrimidine (2.4 g, 0.01M), 30% w/w palladium on charcoal (0.24 g) and diphenyl ether (10 ml) was heated under reflux in an argon atmosphere for 1 hour. The catalyst was then removed by filtration. The filtrate was then diluted with a large volume of hexane (100 ml). This gave a pale yellow solid which was recrystallised from 2-propanol to give 4-(1-indolyl)-6-methyl-2-methylaminopyrimidine (1.47 g, 62%), m.p. 160-162°C; microanalysis, found: C, 70.5; H, 5.9; N, 23.6%; $C_{14}H_{14}N_4$ requires C, 70.6; H, 5.9; N, 23.5%.

The 4-(1-indolyl)-6-methyl-2-methylaminopyrimidine was obtained in 45% yield as its hydrochloride salt, m.p. >300°C using a similar procedure to that described for the analogous intermediate in Example 20 but by reacting 4-chloro-6-methyl-2-methylaminopyrimidine with indoline.

Example 51

A mixture of 2-methyl-6-methylamino-4-N-ethylanilino-pyrimidine (0.7 g, 2.9 mM), methyl iodide (0.54 ml, 8.7 mM) and dioxan (20 ml) was heated at reflux for 15 hours. The mixture was cooled. The solvent was removed in vacuo and the residual syrup was crystallised by addition of acetone. The solid was collected by filtration, washed with acetone and then recrystallised from ethyl acetate to give 1,2-dimethyl-6-methylamino-4-N-ethylanilinopyridinium iodide (0.55 g, 50% yield), m.p. 175-177°C; microanalysis, found: C, 46.8; H, 5.5; N, 14.3%; $C_{15}H_{21}N_5I$ requires: C, 46.88; H, 5.5; N, 14.58%; NMR: 1.1-1.2(3H, t, CH_2CH_3), 2.6(3H, s, CH_3), 2.6-2.7(3H, d, $NHCH_3$) 3.5(3H, s, N- CH_3), 3.9-4.1(2H, q, CH_2CH_3), 5.15(1H, s, pyrimidine 5-H), 7.3-7.65(5H, complex, aromatic), 7.8-7.95(1H, br, NH).

[Note: the site of quaternisation was confirmed by conventional Nuclear Overhauser studies].

The pyrimidine starting material was prepared as follows:-

A mixture of 4-chloro-2-methyl-6-methylaminopyrimidine (2.0 g, 12.7 mM) and N-ethylaniline (3.06 g, 25.4 mM) was heated as a melt at 160°C for 3 hours. The residue was cooled and acetone (10 ml) added. The resultant solid was collected by filtration and washed

with acetone. There was thus obtained 2-methyl-6-methylamino-4-N-ethylanilinopyrimidine (2.25 g) as the hydrochloric salt. This salt (2.25 g, 7.9 mM) was dissolved in 2-propanol (50 ml) and a solution of potassium hydroxide (0.44 g, 7.9 mM) dissolved in the minimum volume of water was added. The mixture was heated at 90°C for 5 minutes. The solvent was removed in vacuo. The resultant solid was stirred with water (25 ml) and then collected by filtration, washed with water and then dried at 100°C to give 2-methyl-6-methylamino-4-N-ethylanilinopyrimidine (1.4 g, 46% yield), m.p. 144-145°C; microanalysis, found: C, 69.1; H, 7.5; N, 22.8%; $C_{14}H_{18}N_4$ requires C, 69.4; H, 7.5; N, 23.1%.

Examples 52-54

The procedure described in Example 51 was repeated using the appropriate substituted pyrimidine of formula III and alkylating agent of formula $R^1.Y$. There were thus obtained the following compounds of formula I (A=direct bond, $R^1=R^2=CH_3$, $R^5=H$; Y^- =iodide):-

(Example 52): 1,2-dimethyl-6-amino-4-N-ethylanilinopyrimidinium iodide, as a solid, m.p. 195-196°C (recrystallised from ethyl acetate) in 65% yield;

(Example 53): 1,2-dimethyl-6-methylamino-4-N-methylanilinopyrimidinium iodide, as a solid, m.p. 198-200°C (recrystallised from 2-propanol) in 50% yield; and

(Example 54): 1,2-dimethyl-6-ethylamino-4-N-methylanilinopyrimidinium iodide, as a solid, m.p. 212-213°C (recrystallised from acetone) in 49% yield.

The necessary starting materials were made in an analogous manner to that described for the starting material of Example 51 and had the following properties:-

- a) 6-amino-2-methyl-4-N-ethylanilinopyrimidine, as a solid, m.p. 126-127°C (trituated with ether) in 71% yield;
- b) 2-methyl-6-methylamino-4-N-methylanilinopyrimidine, as a solid, m.p. 123-124°C (trituated with ether) in 60% yield; and
- c) 6-ethylamino-2-methyl-4-N-methylanilinopyrimidine, as a solid, m.p. 87-89°C (trituated with methylene chloride) in 80% yield.

Example 55

Using a similar procedure to that described in Example 51, 1,2-dimethyl-4-(1-indolyl)-6-aminopyrimidinium iodide was obtained as a crystalline solid in 27% yield, m.p. 286°C (with decomposition), (after recrystallisation from methanol), by reaction of 6-amino-4-(1-indolyl)-2-methylpyrimidine with methyl iodide.

The starting material was prepared as follows:-

A mixture of 6-amino-4-(1-indolyl)-2-methylpyrimidine (4.5 g, 20 mM), 30% w/w palladium on charcoal (0.45 g) and diphenyl ether (15 ml) was heated under reflux in an argon atmosphere for 1 hour. The solid was removed by filtration and the filtrate was diluted with hexane (100 ml) to give 6-amino-4-(1-indolyl)-2-methylpyrimidine (4.25g, 95%) as a pale yellow solid, m.p. 176-177°C; microanalysis, found: C, 69.5; H, 5.5; N, 24.4%; $C_{13}H_{12}N_4$ requires C, 69.64; H, 5.36; N, 25.0%.

The 6-amino-4-(1-indolyl)-2-methylpyrimidine was obtained as a solid, m.p. 209-210°C, in a similar number to that described for the analogous intermediate in Example 51 by reaction of 6-amino-4-chloro-2-methylpyrimidine with indoline.

Example 56

A column of quaternary ammonium hydroxide anion exchange resin was prepared from Amberlite* IRA400 (chloride form) by eluting the resin with sodium hydroxide (1M solution) until the eluate was free of chloride ions and then washing with deionised water (until the eluate was pH=7) and then with 10% v/v ethanol/water (500ml). A mixture of 1,2-dimethyl-6-methylamino-4-N-ethylanilinopyrimidinium iodide (10.0g) and 10% v/v ethanol/water (200ml) was then loaded onto the column (approximate resin volume 100ml). The column was eluted with 10% v/v ethanol/water (1l). The white solid which crystallised from the eluate was collected by filtration and recrystallised from ethanol/water to give 1,2-dimethyl-6-methylamino-4-N-ethylanilino-pyrimidine (0.93g), m.p. 82-83°C; microanalysis, found: C, 70.1; H, 7.8; N, 21.9%; $C_{15}H_{20}N_4$ requires: C, 70.3; H, 7.84; N, 21.86%; NMR (200MHz, DMSO-d₆): 1.09(3H, t, -CH₂CH₃); 2.38(3H, s, pyrimidine-2-CH₃); 2.53(3H, s, =N-CH₃); 3.36(3H, s, pyrimidine N(1)-CH₃);

3.88(2H,q,-CH₂CH₃); 4.78(1H,s, pyrimidine 5-H); 7.22-7.34(3H, complex, aromatic), 7.40-7.50(2H, complex, aromatic).

The filtrate was distilled under reduced pressure to reduce the volume to about 400ml. The pH of the solution was adjusted, carefully to 6.65 by addition of M-hydrochloric acid. The mixture was then evaporated to dryness and triturated with ethyl acetate. The white crystalline solid was recrystallised from a mixture of ethyl acetate and 2-propanol to give 1,2-dimethyl-6-methylamino-4-N-ethylanilinopyrimidinium chloride (4.69g), m.p. 201.5-202.5°C, microanalysis, found C, 61.2;H, 7.3;N, 19.1%; C₁₅H₂₁N₄Cl requires: C, 61.5;H, 7.2;N, 19.1%; NMR (200MHz, DMSOd₆): 1.14(3H,t,-CH₂CH₃); 2.61(3H,s,pyrimidine-2-CH₃); 2.63(3H,s,NHCH₃); 3.65 (3H,s, pyrimidine-N(1)-CH₃); 4.01(2H,q,-CH₂-CH₃); 5.13 (1H,s,pyrimidine-5-H); 7.32-7.61(5H, complex, aromatic), 8.87 (1H,s,NH).

[* Amberlite is a trade mark, the property of the Rohm and Haas Co.]

Examples 57-76

Using a similar procedure to that described in Example 20, the following compounds of formula I (R¹=R⁶=CH₃, R⁵=H; Y⁻=iodide) were obtained:-

Example	R ²	R ⁴	Q.A	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
57	NHMe	Et	4-methyl-phenyl	MeOH/EtOAc	196-199	88
58	NH.crotyl	H	phenyl	MeOH/EtOAc	220-221	14
59	NHMe	2-butynyl	phenyl	Pr ⁱ OH	191-183	47
60	NH ₂	2-propynyl	phenyl	Pr ⁱ OH	232-234 (dec.)	62

Example	R ²	R ⁴	Q.A	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
61	NHEt	Et	phenyl	Pr ⁱ OH	172-173	39
62	NHEt	Me	phenyl	Pr ⁱ OH	183-184	39
63	NHEt	allyl	phenyl	EtOAc	104-106	46
64	NHPr ⁱ	Me	phenyl	Pr ⁱ OH/Et ₂ O	165-166	37
65	NHBu	Me	phenyl	Me ₂ CO/Et ₂ O ⁺	146-147	40

Note: crotyl is equivalent to 2-butenyl + triturated with solvent

The following compounds of formula I (R⁶=CH₃, R⁵=H,
Q.A-phenyl; Y⁻=iodide) were obtained in a similar manner:-

Example	R ¹	R ²	R ⁴	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
66	Et	NH ₂	H	H ₂ O	263-265 (dec.)	63
67	Et	NH ₂	Me	Pr ⁱ OH	213-214	39
68	Pr	NH ₂	Me	Me ₂ CO	199-202	13
69	Et	NHMe	Et	Pr ⁱ OH	146-148 (dec.)	58
70	Et	NH ₂	Et	Pr ⁱ OH	223-224	39
71	Pr	NH ₂	Et	cyclohexane	184-188	31
72	allyl	NH ₂	Et	Pr ⁱ OH	202-203	35
73	Me	piperidino	Et	CH ₂ Cl ₂ ⁺	160-162	17

+ triturated with solvent

(Example 74): 2-amino-1-ethyl-4-(3,5-dimethylanilino)-6-methylpyrimidinium iodide was similarly obtained as a solid in 28% yield, m.p. 226-227°C, by reaction of 2-amino-4-(3,5-dimethylanilino)-6-methylpyrimidine with ethyl iodide;

(Example 75): 2-amino-1,6-dimethyl-4-(2-methyl-1,2,3,4-tetrahydro-1-quinolylamino)pyrimidinium iodide was similarly obtained as a solid in 32% yield, m.p. 216-218°C, by reaction of 2-amino-6-methyl-4-(2-methyl-1,2,3,4-tetrahydro-1-quinolylamino)pyrimidine with methyl iodide; and

(Example 76): 2-amino-1,6-dimethyl-4-(2,4-dimethyl-1,2,3,4-tetrahydro-1-quinolylamino)pyridinium iodide was similarly obtained as a solid in 8% yield, m.p. 140-142°C, by reaction of 2-amino-6-methyl-4-(2,4-dimethyl-1,2,3,4-tetrahydro-1-quinolylamino)pyrimidine with methyl iodide.

The necessary starting pyrimidines of formula III ($R^6=CH_3$, $R^5=H$) were obtained in an analogous manner to that described for the starting material of Example 20 and had the following properties:-

[Note: the starting material for Example 60 was made by alkylation of a solution of the starting material for Example 66 in DMF with propargyl bromide using sodium hydride as base.]

III for Ex. no.	R^2	R^4	Q.A	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
57	NHMe	Et	4-methyl- phenyl	Note (a)	138-140	44
58	NH.crotyl	H	phenyl	Note (a)	oil	28
59	NHMe	2-butyryl	phenyl	EtOAc	141-143	57
60	NH ₂	-CH ₂ -C≡CH	phenyl	cyclohexane	106-108	50

III Ex. no.	f r R ²	R ⁴	Q.A	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
61	NHEt	Et	phenyl	Note (a)	91-93	76
62	NHEt	Me	phenyl	hexane	89-90	37
63	NHEt	allyl	phenyl	Pr ⁱ OH	112-113	61
64	NHPr	Me	phenyl	Et ₂ O	77-79	85
65	NHBu	Me	phenyl	Note (a)	146-147	54
66	NH ₂	H	phenyl	EtOAc	161-163	48
67,68	NH ₂	Me	phenyl	hexane/ EtOAc	148-150	35
69	NHMe	Et	phenyl	hexane	125-127	62
70-72	NH ₂	Et	phenyl	Note (a)	113-114	64
73	piperidino	Et	phenyl	----	oil	99
74	NH ₂	H	3,5-Me ₂ - phenyl	EtOAc/hexane	171-173	63

Notes: crotyl is equivalent to 2-butenyl
 (a): purified by chromatography on silica using ethyl acetate/hexane as eluant.

 The starting 2-butylamino-4-chloro-6-methylpyrimidine needed to prepare the compound III for Example 65 was prepared as follows:-

2-Butylamino-6-methylpyrimidin-4-one (8.4 g, 0.046 M) was treated with phosphorus oxychloride (5 ml). A vigorous reaction ensued. When this had subsided, the resultant mixture was heated at 90°C for 30 minutes. This gave an orange coloured syrup which was cooled and added to water to decompose the excess phosphorus oxychloride. The aqueous solution was adjusted to pH 7 using 2M sodium hydroxide solution. The resultant white precipitate was extracted with methylene chloride. The extracts were dried (MgSO₄) and the solvent evaporated to give 2-butylamino-4-chloro-6-methylpyrimidine (8.1 g) as a solid, m.p. 35-36°C, in 88% yield.

The starting 4-anilino-2-crotylamino-6-methylpyrimidine required to prepare the compound III for Example 58 was prepared as follows:-

A mixture of 2-amino-4-anilino-6-methylpyrimidine (1 g) (5mM), potassium carbonate (0.4 g, 5.5 mM), crotyl bromide (0.61 ml) (5mM) and acetone (25 ml) was heated at reflux for 20 hours. The solvent was then evaporated and the residue triturated with methylene chloride. The methylene chloride extracts were combined and the solvent removed by evaporation. The residual syrup was purified by flash chromatography using Merck 9835 silica (200 g) and eluting with 5% v/v methanol/methylene chloride. There thus was obtained 4-anilino-2-crotylamino-6-methylpyrimidine as a viscous oil (0.36 g) which was used without characterisation.

The starting 2-amino-6-methyl-4-(2-methyl-1,2,3,4-tetrahydro-1-quinolylamino)pyrimidine for Example 75 was obtained as a solid in 32% yield, m.p. 140-142°C, by reaction of 4-chloro-6-methyl-2-methylamino-pyrimidine with 2-methyl-1,2,3,4-tetrahydroquinoline. Similarly, the starting 2-amino-6-methyl-4-(2,4-dimethyl-1,2,3,4-tetrahydro-1-quinolylamino)pyrimidine for Example 76, was obtained as a solid in 44% yield, m.p. 144-146°C, by reaction of 4-chloro-6-methyl-2-methylaminopyrimidine with the known compound 2,4-dimethyl-1,2,3,4-tetrahydroquinoline (Chemical Abstracts Registry No. 67525-06-8).

Examples 77-102

The procedure described in Example 20 was repeated using the appropriate substituted pyrimidine of formula III and alkylating agent

of formula R¹.I . There were thus obtained the following compounds of formula I (Q.A=phenyl, R⁵=H, Y⁻=iodide):-

Example	R ¹	R ²	R ⁴	R ⁶	Recrystallisation solvent(s)	m.p. (°C)	yield (%)
77	Me	NH ₂	Me	Et	MeOH/Et ₂ O	226-230 ⁺	64
78	Me	NH ₂	Me	Pr	dioxan	206-210*	62
79	Me	NH ₂	Me	Bu	Pr ⁱ OH/Et ₂ O	173-174	62
80	Me	NH ₂	Me	Bu ⁱ	Pr ⁱ OH/Et ₂ O	167-168	48
81	Me	NH ₂	Me	PhCH ₂ CH ₂	Pr ⁱ OH/Et ₂ O	175-180	44
82	Me	NH ₂	Me	3-butenyl	Pr ⁱ OH/Et ₂ O	148-150	53
83	Et	NH ₂	Me	Et	MeOH/Et ₂ O	194-196*	23
84	Et	NH ₂	Me	Pr	MeOH/Et ₂ O	199-201*	18
85	Me	NHMe	Me	Et	MeOH/Et ₂ O	208-210*	26
86	Me	NH ₂	Et	Et	MeOH/Et ₂ O	236-238*	16
87	Me	NH ₂	Et	Pr	MeOH/Et ₂ O	198-200*	59
88	Me	NH ₂	Et	Bu	Pr ⁱ OH/Et ₂ O	147-148	35
89	Me	NH ₂	Et	pentyl	Pr ⁱ OH/Et ₂ O	164-166	66

Example	R ¹	R ²	R ⁴	R ⁶	Recrystallisation solvent(s)	m.p. (°C)	yield (%)
90	Me	NH ₂	Et	3-butenyl	Pr ⁱ OH/Et ₂ O	133-134	39
91	Me	NH ₂	Et	EtOCH ₂	Pr ⁱ OH/Et ₂ O	208-212	74
92	Me	NHMe	Et	Et	MeOH/Et ₂ O	158-160	35
93	Me	NHMe	Et	Pr	MeOH/Et ₂ O	143-145	31
94	Et	NH ₂	Et	Et	MeOH/Et ₂ O	190-192*	38
95	Et	NH ₂	Et	Pr	MeOH/Et ₂ O	196-198*	51
96	Me	NHEt	Me	Et	MeOH/Et ₂ O	183-186 ⁺	48
97	Me	NHEt	Me	Pr	MeOH/Et ₂ O	168-170 ⁺	39
98	Me	NHEt	Et	Et	MeOH/Et ₂ O	160-163*	44
99	Me	NHEt	Et	CH ₂ OEt	Pr ⁱ OH/Et ₂ O	130-131	58
100	Et	NHEt	Et	Et	MeOH/Et ₂ O	165-167	29

Notes: * Melting point accompanied by decomposition
 + obtained as a partial methanolate (0.5 MeOH)

 The necessary starting pyrimidines of formula III (Q.A=phenyl, R⁵=H) were made in an analogous mannner to that described for the starting material of Example 20 and had the following properties:-

III for Ex. No.	R ²	R ⁴	R ⁶	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
77,83	NH ₂	Me	Et	Et ₂ O	105-106	14
78,84	NH ₂	Me	Pr	Et ₂ O/hexane	104-106	24
79	NH ₂	Me	Bu	hexane	66-67	65
80	NH ₂	Me	Bu ⁱ	hexane	107-109	78
81	NH ₂	Me	PhCH ₂ CH ₂	Et ₂ O/hexane	110-111	55
82	NH ₂	Me	3-butenyl	hexane	46-48	46
85	NHMe	Me	Et	+	84-88	17
86	NH ₂	Et	Et	+	115-117	87
87	NH ₂	Et	Pr	+	93-95	64
88	NH ₂	Et	Bu	hexane	87-88	44
89	NH ₂	Et	pentyl	hexane	102-103	86
90	NH ₂	Et	3-butenyl	hexane	79-81	46
91	NH ₂	Et	EtOCH ₂	+	126-128	32

III for Ex. No.	R ²	R ⁴	R ⁶	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
92	NHCH ₃	Et	Et	+	118-122	11
93	NHCH ₃	Et	Pr	+	80-82	8
96	NHEt	Me	Et	+	oil	20
97	NHEt	Me	Pr	+	oil	44
98,100	NHEt	Et	Et	+	68-72	61
99	NHEt	Et	EtOCH ₂	hexane	50-51	55

+ purified by flash chromatography on silica using 0.5% v/v methanol in dichloromethane as eluant and used without further purification.

The following compounds of formula I were obtained in a similar manner:-

(Example 101): 2-amino-4-(N-ethylanilino)-5,6,7,8-tetrahydro-1-methylquinazolinium iodide obtained as a partial hydrate (0.25 H₂O), m.p. 221-223°C (after recrystallisation from methanol/ether) in 48% yield by reaction of methyl iodide with 2-amino-(4-N-ethylanilino)-5,6,7,8-tetrahydroquinazoline; [the latter compound was itself obtained as a solid, m.p. 132-134°C, in 11% yield by reaction of 2-amino-4-chloro-5,6,7,8-tetrahydroquinazoline with N-ethylaniline;].

(Example 102): 2-amino-4-(N-ethylanilino)-1-methylquinazolinium iodide was similarly obtained as a solid. m.p. 252-254°C (dec.) (recrystallised from methanol/ether) in 37% yield by reaction of methyl iodide with 2-amino-(4-N-ethylanilino)-quinazoline; [the latter compound was itself obtained as a solid, m.p. 168-170°C, in 11% yield by reaction of 2-amino-4-chloroquinazoline with N-ethylaniline;]

Certain of the chloropyrimidines of formula IV ($X=Cl$, $R^5=H$) which were used as starting materials in Examples 77-102 are known compounds, and are described in the following references:-

- (a) $R^6=H$, $R^2=NH_2$; Tetrahedron, 1968, 24, 3595;
- (b) $R^6=Et$, $R^2=NH_2$; Belgian Patent no. 657, 135, Jan 15, 1965; and
- (c) $R^6=CH_2CH_2Ph$, $R^2.NH_2$; J. Org. Chem., 27, 1717.

The method by which the other chloropyrimidines of formula IV ($X=Cl$, $R^5=H$) were prepared is illustrated by the following preparation of 4-chloro-2-ethylamino-6-propylpyrimidine:-

(a) Ethyl 3-oxo-hexanoate (4.74 g; 30 mM) and N-ethylguanidine sulphate (4.08 g; 30 mM) were dissolved in a solution prepared by dissolving sodium (1.4 g; 0.65 g atom) in ethanol (100 ml) and the mixture was heated under reflux on the steam bath for 18 hours.

Acetic acid (5 ml) was added to the cooled mixture which was stirred for 10 minutes. Insoluble material was removed by filtration and the filtrate was evaporated. The residue was partitioned between water (50 ml) and methylene chloride (50 ml). The aqueous layer was extracted twice with methylene chloride (50 ml). The combined extracts were dried and the solvent evaporated. The residue was crystallised from cyclohexane to give 2-ethylamino-4-hydroxy-6-propylpyrimidine as a solid (4.6 g; 85% yield), m.p. 108-110°C.

(b) A mixture of 2-ethylamino-4-hydroxy-6-propylpyrimidine (1.81 g, 10 mM) and phosphorus oxychloride (15 ml) was heated at 100°C for 18 hours. The excess of phosphorus oxychloride was removed under reduced pressure and the residual was decomposed with ice-water (50 ml). The solution was made basic with concentrated aqueous ammonia and extracted with ethyl acetate (3 x 50 ml). The extracts were combined, dried and the solvent evaporated to give 4-chloro-2-ethylamino-6-propylpyrimidine (1.79 g; 90% yield) as an oil which was used without purification.

Other chloropyrimidines of formula IV ($X=Cl$, $R^5=H$) were obtained using a similar procedure from the corresponding hydroxypyrimidines of formula IV ($X=OH$, $R^5=H$). The latter compounds had the following properties:-

Number	R ²	R ⁶	Recryst. solvent(s)	M.P. (°C)	Yield (%)
1	NH ₂	Bu	+	212-216	85
2	NH ₂	Bu ⁱ	+	231-234	30
3	NH ₂	3-butenyl	+	186-189	83
4	NH ₂	pentyl	+	188-191	79
5	NH ₂	EtOCH ₂	+	244-245	69
6	NHMe	Et	EtOAc	204-208	46
7	NHMe	Pr	EtOAc	190-192	54
8	NHEt	Et	cyclohexane	144-116	39
9	NHEt	CH ₂ OEt	cyclohexane	106-108	54

+ Triturated with ether and used without further purification

The majority of chloropyrimidines of formula IV (X=Cl, R⁵=H) were used without characterisation, but the following were characterised:-

Number	R ²	R ⁶	Recryst. solvent(s)	M.P. (°C)	Yield (%)
1	NH ₂	Bu	Et ₂ O/hexane	58-59	50
2	NH ₂	Bu ⁱ	Et ₂ O/hexane	104-106	33
3	NH ₂	pentyl	Et ₂ O/hexane	58-59	29

The starting 2-amino-4-chloroquinazoline derivatives (from which the 2-amino-4-N-ethylanilino starting materials for Examples 101 and 102 were prepared) were obtained in an analogous manner to the above chloropyrimidines and were used without purification.

The starting 2-amino-4-hydroxyquinazoline derivatives were themselves obtainable as solids, m.p. >300°C using literature procedures (for example 2-amino-5,6,7,8-tetrahydro-4-hydroxyquinazoline Chem. Pharm. Bull. (Japan), 1986, 34, 4150; 2-amino-4-hydroxyquinazoline: Rec. trav. chim. Pays. Bas., 1960, 79, 443).

Examples 103-109

Using a similar procedure to that described in Example 47, the following compounds of the formula 1 (as set out hereinafter) were obtained:-

Example	X	R ⁴	Recryst. solvent(s)	M.P. (°C)	Yield (%)
103	H	Pr	Me ₂ CO *	250-255	25
104	H	2-butynyl	Me ₂ CO	182-184	47
105	H	Eu	Pr ⁱ OH/Et ₂ O	184-186	25
106	2-MeO	Et	Pr ⁱ OH/Et ₂ O	267-269	12
107	2-Me	Et	CH ₂ Cl ₂ *	216-217	22
108	4-Cl	Et	MeOH/Et ₂ O	244-246	42
109	4-Me	Et	MeOH/Et ₂ O	240-242	32

* triturated with solvent

Examples 110-112

Using an analogous procedure to that described in Example 20, but starting from the appropriate 4-(indol-1-yl)-6-methyl-pyrimidine of formula 2 (as set out hereinafter) and alkylating agent of formula $R^1.I$, the following compounds of the formula 3 (set out hereinafter; $R^6=CH_3$) were obtained:-

Example	R^1	R^2	X	B	Recryst. Solvent(s)	M.P. (°C)	Yield (%)
110	Et	NHMe	H	H	Dioxan *	294-295	6
111	Me	NHMe	H	2-Me	EtOH/H ₂ O	301-302+	43
112	Me	NHMe	5-MeO	H	EtOH/H ₂ O	304-305+	31
113	Me	NH ₂	H	H	EtOH/Et ₂ O	295-296	55
114	Et	NH ₂	H	H	EtOH *	284-286	7
115	Me	NH ₂	5-MeO	H	H ₂ O/EtOH	297-298	47
116	Me	NH ₂	H	2-Me	EtOH/H ₂ O	286-288	43
117	Me	NH ₂	5-Cl	H	EtOH/H ₂ O	288-290	37
118	Me	NH ₂	5-CN	H	EtOH	280-282	10
119	Me	NH ₂	5-Br	H	EtOH/H ₂ O	295-296	41
120	Me	NH ₂	5-Me	H	EtOH/H ₂ O	287-288	37
121	Me	NH ₂	7-aza	H	EtOH/H ₂ O	285+	9
122	Me	NH ₂	5-F	H	MeOH	279-281	15

+ with decomposition

* triturated with solvent

The indolyl starting materials for Examples 110 and 113 were prepared in a similar manner to Example 20 and Example 50 by dehydrogenating the appropriate 4-(indolin-1-yl)pyrimidine with 30% w/w palladium-on-charcoal heated under reflux with diphenyl ether in an argon atmosphere. The required starting 2-amino-4-(1-indolinyl)-6-methylpyrimidine was obtained as a solid, m.p. 242-244°C in 48% yield in a similar manner to that described for the analogous intermediate in Example 13 by reaction of 2-amino-4-chloro-6-methylpyrimidine with indoline.

The remaining indolyl starting materials of formula 2 were obtained by alkylation of the appropriate indole with the required chloropyrimidine in DMF using as base a 60% w/w dispersion of sodium hydride in mineral oil.

The following 4-(indol-1-yl)-6-methylpyrimidine derivatives of formula 2 ($R^6=CH_3$) were thus obtained :-

Cpd. 2 for Ex.	R^2	X	B	Recryst. solvent(s)	m.p. (°C)	yield (%)
110	NHMe	H	H	Pr ⁱ OH	160-162	62
111	NHMe	H	2-Me	cyclohexane	163-165	54
112	NHMe	5-MeO	H	EtOAc	188-189	47
113,114	NH ₂	H	H	CH ₂ Cl ₂ *	178-180	56
115	NH ₂	5-MeO	H	EtOH	179-180	28
116	NH ₂	H	2-Me	EtOAc	186-188	48
117	NH ₂	5-Cl	H	EtOAc	193-195	42
118	NH ₂	5-CN	H	EtOAc	210-212	56

Cpd. 2 for Ex.	R ²	X	B	Recryst. solvent(s)	m.p. (°C)	yield (%)
119	NH ₂	5-Br	H	Me ₂ CO	194-196	21
120	NH ₂	5-Me	H	EtOAc	186-188	33
121	NH ₂	7-aza	H	cyclohexane	171-173	35
122	NH ₂	5-F	H	EtOAc	198-200	38

* triturated with solvent

Examples 123-125

Using a similar procedure to that described in Example 20, the following compounds of formula I were obtained:-

(Example 123): 1,6-dimethyl-4-(indolin-1-yl)-2-methylamino-pyrimidinium iodide, as a solid, m.p. >300°C (recrystallised from DMF), in 74% yield, starting from 4-(indolin-1-yl)-6-methyl-2-methylaminopyrimidine [described above in connection with Example 50];

(Example 124): 2-amino-1,6-dimethyl-4-(indolin-1-yl)pyrimidinium iodide, as a solid, m.p. 274-276 (recrystallised from ethanol), in 43%, starting from 2-amino-4-(indolin-1-yl)-6-methylpyrimidine, itself obtained in 64% yield as a solid, m.p. 157-159°C (recrystallised from cyclohexane), using a similar procedure to that for the analogous starting material in Example 50, but using 2-methylindoline instead of indoline; and

(Example 125): 2-amino-1,6-dimethyl-4-(2,3-dimethylindolin-1-yl)pyrimidinium iodide, as a solid, m.p. 279-281°C (recrystallised from ethanol), in 55% yield, starting from 2-amino-6-methyl-4-(2,3-dimethylindolin-1-yl)pyrimidine, itself obtained in 50% yield as a solid, m.p. 179-181°C (recrystallised from ethyl acetate) using a similar procedure to that for the analogous starting material in Example 50, but using 2,3-dimethylindoline instead of indoline.

Examples 126-130

Using a similar procedure to that described in Example 51, but starting with the appropriate substituted pyrimidine of formula III and methyl iodide, the following compounds of formula I (Q.A=phenyl; $R^1=R^2=CH_3$, $R^5=H$; Y=iodide) were obtained:-

Example	R^4	R^6	Recryst. solvent(s)	M.P. (°C)	Yield (%)
126	Me	NH ₂	2-propanol	228-230	86
127	allyl	NHMe	EtOAc/MeOH	68-71	59
128	2-butyryl	NHMe	EtOAc/MeOH	syrup	15
129	Pr	NHMe	EtOAc	139-140	38
130	Pr ^C .CH ₂	NHMe	EtOAc	147-149	47

Note: Pr^C = cyclopropyl

The necessary starting materials of formula III were made in an analogous manner to that described for the starting materials of Example 51 from the appropriate chloropyrimidines of formula IV (X = Cl) and had the following properties:-

III for Ex. no.	R^4	R^6	Recryst. solvent(s)	M.P. (°C)	Yield (%)
126	Me	NH ₂	CH ₂ Cl ₂	128-130	53
127	allyl	NHMe	Et ₂ O	98-101	43
128	2-butyryl	NHMe	---	syrup	45
129	Pr ⁿ	NHMe	hexane	114-114.5	53
130	Pr ^C .CH ₂	NHMe	hexane	98-100	28

Note: Pr^C = cyclopropyl

* having a satisfactory NMR spectrum

Examples 131-135

The procedure described in Example 51 was repeated using the appropriate substituted pyrimidine of formula III and methyl iodide. There were thus obtained the following compounds of formula I (Q.A=phenyl, $R^1=CH_3$, $R^5=H$, $R^6=NHCH_3$; Y^- =iodide):-

Example	R^4	R^2	Recryst. solvent(s)	M.P. (°C)	Yield (%)
131	Me	Et	Pr^iOH/Et_2O	173-174	41
132	Me	H	Pr^iOH/Et_2O	172-173	81
133	Et	Et	EtOAc	146-147	44
134	Et	Pr	Me_2CO/Et_2O	127-130	27
135	Et	Bu	$MeOH/Et_2O$	144-146	19

The necessary starting materials of formula III (Q.A=phenyl; $R^2=CH_3$, $R^5=H$) were made in an analogous manner to that described for the starting material of Example 51 from the appropriate chloropyrimidine of formula IV ($X = Cl$) and had the following properties:-

No.	R^4	R^2	Trituration solvent(s)	M.P. (°C)	Yield (%)
131	Me	Et	CH_2Cl_2	98-100	71
132	Et	H	Pr^iOH/Et_2O	113-114	44
133	Et	Et	CH_2Cl_2	97-99	63.5
134	Et	Pr	CH_2Cl_2	69-71	22
135	Et	Bu	hexane	75-75.5	31

The required chloropyridine starting materials of formula (IV) are themselves prepared by the addition of the appropriate 2-substituted-4,6-dichloropyrimidine to an alcoholic solution of the required amine with cooling below 10°C. The reaction mixture was then allowed to warm to ambient temperature and the solvent evaporated. The residue was partitioned between water and methylene chloride. The organic phase was dried (MgSO_4) and concentrated in vacuo to give the required compound of formula IV ($\text{X}=\text{Cl}$):-

- (a) 4-chloro-2-ethyl-6-methylaminopyrimidine, obtained as a solid, m.p. 80-81°C;
- (b) 4-chloro-6-methylamino-2-propylpyrimidine, obtained as a solid, m.p. 30-40°C; and
- (c) 2-butyl-4-chloro-6-methylaminopyrimidine, obtained as an oil.

Examples 136-139

The procedure described in Example 51 was repeated using the appropriate substituted pyrimidine of formula III and alkylating agent of formula $\text{R}^1\text{.Y}$. There were thus obtained the following compounds of formula I ($\text{R}^4=\text{Et}$, $\text{R}^2=\text{CH}_3$, $\text{R}^5=\text{H}$, $\text{R}^6=\text{NHCH}_3$):-

A=direct bond;

Example	Q.A-	R^1	Y	Recryst. solvent(s)	m.p. (°C)	yield (%)
146	p-tolyl	Me	I	MeOH/ Et_2O	188-191	31
147	p-anisyl	Me	I	EtOH	211-214	40
148	p-Cl-phenyl	Me	I	MeOH/ Et_2O	243-245	60
149	phenyl	Et	BF_4	EtOAc*	126-128	8

* triturated with solvent

The necessary starting materials of formula III were made in an analogous manner to that described for the starting material of Example 51, but using the appropriate N-ethylaniline:-

a) 4-(N-ethyl-4-methylanilino)-2-methyl-6-methylaminopyrimidine obtained as a solid, m.p. 140-143°C, in 70% yield;

(b) 4-(N-ethyl-4-methoxyanilino)-2-methyl-6-methylaminopyrimidine, obtained as a solid, m.p. 116-118°C, in 71% yield; and

(c) 4-(N-ethyl-4-chloroanilino)-2-methyl-6-methylaminopyrimidine, obtained as a solid, m.p. 133-136, in 79% yield.

[Note: the required starting material of formula III for Example 139 is described in Example 51].

Examples 140-144

Using a similar procedure to that described in Example 56, the following 1,2-dimethyl-6-methylamino-4-N-ethylanilinopyrimidium salts were obtained by reacting 1,2-dimethyl-6-methylimino-4-N-ethylanilinopyrimidine with the appropriate acid:-

Example	Salt	Recryst. solvent(s)	M.P. (°C)	Yield (%)
140	fumarate	acetonitrile	152-154	80
141	benzoate	hexane *	46-47	93
142	hydrogen sulphate	Pr ⁱ OH/Et ₂ O	146-147	58
143	acetate	hexane *	43-45	62
144	butyrate	Et ₂ O/hexane	52-58	56

* triturated with solvent

Examples 145-154

Using a similar procedure to that described in Example 51, but starting from the appropriately substituted 4-(indol-1-yl)-pyrimidine of formula 2 and methyl iodide, the following 4-(indol-1-yl)-1,2-dimethyl-6-methylaminopyrimidinium salts of the formula 3 ($R^1=R^2=CH_3$ and $R^6=NHCH_3$, except where stated) were obtained:-

Example	X	B	Recryst. solvent(s)	M.P. (°C)	Yield (%)
145	H	H	MeOH	270-272 (decomp.)	14
146 +	H	3-Me	MeOH	276-277	7
147	H	3-Me	EtOH/H ₂ O	257-258	24
148	H	3-Et	EtOH	259-260	16
149 *	H	3-Et	EtOH	249-250	24
150 **	H	3-Et	EtOH	240-242	21
151	H	3-Pr	EtOH	245-247	35
152	H	3-Ph	MeOH/H ₂ O	254.5-255.5	20
153	H	3-Pr ⁱ	H ₂ O	251-252	4
154	5-MeO	H	MeOH	309-310	8

+ $R^6=NH_2$ * $R^2=Et$ ** $R^6=NHEt$

The starting 4-(indol-1-yl)pyrimidines of formula 2 for Examples 145, 149 and 150 were obtained from the appropriate indoline and

chloropyrimidine using a similar procedure to that used for the analogous starting material in Example 55.

The preparation of the starting 4-(indol-1-yl)pyrimidines of formula 2 for Examples 146, 147 and 151-154 is illustrated by the following preparation of the starting material for Example 148:-

A mixture of 3-ethylindole (1.45 g, 10 mM), sodium hydride (60% w/w oil dispersion) (0.44 g, 11 mM) and dry DMF (10 ml) was stirred under an argon atmosphere. When effervescence had ceased, a mixture of 4-chloro-2-methyl-6-methylaminopyrimidine (1.575 g, 10 mM) and DMF (15 ml) was added. The mixture was stirred at 110°C for 20 hours, cooled, water (10 ml) added and the solvent evaporated. The residue was dissolved in methylene chloride and purified by flash column chromatography on silica (Merck 9385) using ether as eluant to give 4-(3-ethyl-1-indolyl)-2-methyl-6-methylaminopyrimidine as a solid (0.64 g, 25%), m.p. 161-162°C, (after recrystallisation from ethyl acetate); microanalysis, found: C,72.4; H,6.9; N,21.1%; $C_{16}H_{18}N_4$ requires C,72.18; H,6.77; N,21.05%.

The properties of the various starting materials of formula 2 for Examples 145-154 are summarised below:-

Cpd. 2 for Ex.	X	B	R ²	R ⁶	Recryst. solvent(s)	M.P. (°C)	Yield (%)
145	H	H	Me	NHMe	Et ₂ O	153-154	65
146	H	Me	Me	NH ₂	EtOAc	183-184	29
147	H	Me	Me	NHMe	EtOAc/hexane	156-157	32
148	H	Et	Me	NHMe	EtOAc	161-162	25
149	H	Et	Et	NHMe	cyclohexane	128-130	58
150	H	Et	Me	NHEt	cyclohexane	117-118	44
151	H	Pr	Me	NHMe	EtOAc *	144-146	31
152	H	Ph	Me	NHMe	Et ₂ O	151-152	35
153	H	Pr ⁱ	Me	NHMe	hexane	130-131	40
154	5-MeO	H	Me	NH ₂	EtOAc	162-164	31

* triturated with solvent

The 4-(indolin-1-yl)-6-aminopyrimidines of the formula 4 (set out hereinafter) required for the formula 2 starting materials to Examples 145, 149 and 150, respectively, were obtained in a similar manner to that described for the analogous intermediate in Example 51 by reacting the appropriately substituted indoline with the required chloropyridine and had the following properties:-

No.	B	R ₂	R ⁶	Recryst. solvent(s)	m.p. (°C)	yield (%)
1	H	Me	NHMe	Ether/hexane	174-177	93
2	3-Et	Et	NHMe	EtOAc	168-170	32
3	Et	Me	NHEt	MeCN	146-148	17

Examples 155-158

Using a similar procedure to that described in Example 51, the following 1-indolinyl compounds of formula 5 (set out hereinafter) were obtained by reacting the appropriate indoline of formula 4 (R⁶=NHCH₃) with methyl iodide:-

Example	B	R ²	Recryst. solvent(s)	M.P. (°C)	Yield (%)
155	H	Me	EtOH	281-283 +	50
156	3-Me	Me	EtOH	261-262	51
157	3-Et	Et	Ether *	240-241 +	36
158	3-Et	Me	EtOH	262-263	51

* triturated with solvent

+ with decomposition

The starting indolines of formula 4 have either been described hereinabove (i.e. in connection with Examples 145 and 149) or may be obtained in an analogous manner by reaction of the appropriate substituted indoline with the required chloropyrimidine derivative. Thus, the following additional starting materials of formula 4 ($R^6 = \text{NHCH}_3$) were obtained:-

Cpd. No.	B	R ²	Recryst. solvent(s)	m.p. (°C)	yield (%)
4	3-Me	Me	EtOAc	164-165	59
5	3-Et	Me	EtOH	178-180	25

Example 159

A mixture of 4-N-ethylanilino-2-methyl-1-phenylpyrimidin-6-one (0.6 g; 1.76 mM) and phosphorus oxychloride (6 ml) was heated under reflux for 2 hours. The excess phosphorus oxychloride was removed by evaporation. The residue was dissolved in toluene and the solvent evaporated. The process was repeated and the oily residue (containing the corresponding chloride salt of the dichlorophospinoyl derivative of the starting pyrimidinone) was added slowly to a stirred solution of methylamine in ethanol (10 ml of 33% w/w). After 16 hours, the solvent was evaporated. 1M Sodium hydroxide solution (10 ml) was added to the residue and the mixture was extracted with ether (2 x 10 ml). The extracts were dried by filtration through phase-separating paper and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised from ethanol/ether to give 4-N-ethylanilino-2-methyl-6-methylamino-1-phenylpyrimidinium chloride (0.364 g), m.p. >330°C; microanalysis, found: C, 64.8; H, 6.6; N, 15.2; $\text{C}_{20}\text{H}_{23}\text{N}_4\text{Cl} \cdot 0.75\text{H}_2\text{O}$ requires: C, 65.2; H, 6.7; N, 15.2%; NMR (200 MHz): 1.1(3H, t, CH_3), 2.7(3H, s, CH_3), 3.8(3H, s, CH_3), 4.0(2H, q, CH_2), 5.24(1H, s, CH), 7.1-7.3(10H, complex, aromatic H).

The starting material was prepared as follows:-

(i) A mixture of 2-methyl-1-phenyl-1,4,5,6-tetrahydropyrimidin-4,6-dione (obtained by the procedure of L.B. Dashkevich, Dokl. Akad. Nauk. SSSR, 1962, 145, 323), (2.02 g, 10 mM) and phosphorus oxychloride (10 ml) was heated at 100°C for 1 hour. Excess phosphorus oxychloride was removed by evaporation and the residue was added to ice-water with stirring. Sodium carbonate was added to the stirred mixture until there was no more effervescence. The mixture was extracted with methylene chloride (2 x 20 ml) and the extracts were dried by filtration through phase separation paper. The filtrate was diluted to a volume of 250 ml with methylene chloride and subjected to filtration chromatography on silica (Merck 7736). There was thus obtained 4-chloro-2-methyl-1-phenylpyrimidin-6-one (1.1 g), m.p. 109-110°C; NMR (200 MHz): 2.28(3H,s, CH₃), 6.5(1H,s, CH), 7.15-7.6(complex, 5 aromatic H).

(ii) A mixture of the above chloropyrimidinone (1.1 g, 50 mM) and N-ethylaniline (1.81 g, 15 mM) was heated at 180°C (external temperature) under argon for 18 hours. The mixture was cooled and ether (15 ml) was then added. The precipitate of N-ethylaniline hydrochloride was removed by filtration. The filtrate was evaporated and the residue was partitioned between 10% sodium carbonate solution and methylene chloride. The organic layer was dried by filtration through phase separating paper and evaporated. The residue was purified by flash chromatography on silica (Merck 9385) using 3:1 v/v ethyl acetate and hexane to give, after recrystallisation from ethyl acetate/hexane, 4-N-ethylanilino-2-methyl-1-phenylpyrimidin-6-one (0.68 g), m.p. 131-132°C; NMR (200 MHz): 1.21(3H,t, CH₃), 2.1(3H,s, CH₃), 3.9(2H,q, CH₂), 5.1(1H,s, CH), 7.14-7.55 (complex, 10 aromatic H).

Example 160

A mixture of 1,2-dimethyl-4-N-ethylanilinopyrimidin-6-one (1.13 g, 4.65 mM) and phosphorus oxychloride (10 ml) was heated at 100°C for 4 hours. The excess phosphorus oxychloride was removed by evaporation. The residual gum (containing the corresponding chloride salt of the dichlorophospinoyl derivative of the starting pyrimidinone) was dissolved in ethanol (10 ml). To this solution was added dropwise with stirring and ice-cooling, a 32% w/w solution of

methylamine in ethanol (10 ml) so that the temperature did not exceed 30°C. The solution was kept at room temperature for 2 hours after the addition was complete. Solvent was removed by evaporation and the residue was partitioned between 10% w/v sodium carbonate solution (20 ml) and ether (20 ml). The aqueous layer was separated and extracted with methylene chloride (4 x 10 ml). The combined organic extracts were dried (MgSO_4) and evaporated to give a gum (1.3 g) which was crystallised from a mixture of acetone and ether to give 1,2-dimethyl-4-N-ethylanilino-6-methylaminopyrimidinium chloride as a solid (0.81 g), m.p. 202-203°C.

The starting material was prepared as follows:-

- (i) 4-Chloro-6-hydroxy-2-methylpyrimidine (1.3 g, 10 mM) and N-ethylaniline (5 ml) were heated to 200°C under argon for 4 hours. The mixture was cooled to room temperature and treated with ethanol (10 ml). The crystalline solid thus obtained was isolated by filtration, washed with ethanol and dried to give 4-N-ethylanilino-6-hydroxy-2-methylpyrimidine (1.28 g), m.p. 265-266°C; NMR (200 MHz): 1.0-1.1(3H,t, CH_3), 2.0(3H,s, CH_3), 3.9(2H,q, CH_2), 4.5(1H,s, CH), 7.2-7.5 (complex, 5 aromatic H), 11.5-11.64(1H,br, NH).
- (ii) A mixture of the above anilinopyrimidine (1.15 g, 50 mM), methyl iodide (1.9 ml, 0.03 mmol) and potassium hydroxide flake (0.56 g, 10 mM) in ethanol (50 ml) was heated under reflux for 4 hours. Further portions of potassium hydroxide (0.56 g) and methyl iodide (1.9 ml) were then added and heating continued for an extra 3 hours. Solvent was evaporated and the residue was partitioned between 2M sodium hydroxide (25 ml) and ether (25 ml). The ethereal layer was separated, dried (MgSO_4) and the ether evaporated to give 1,2-dimethyl-4-N-ethylanilinopyrimidin-6-one as an oil (1.13 g); NMR (200 MHz): 1.17(3H,t, CH_3), 2.45(3H,s, 6H_3), 3.4(3H,s, CH_3), 3.92(2H,q, CH_2), 5.05(1H,s,CH), 7.1-7.47(complex, 5 aromatic H).

Examples 161-186

The general procedure described in Example 1 was repeated but starting from the appropriate 1,2-disubstituted-6-methylpyrimidin-1-one of formula 6 (set out hereinafter) producing in situ the chloride salt of the dichlorophospinoyl derivative of the starting

pyrimidin ne, which latter is then reacted with N-ethylaniline or N-methylaniline to give the following compounds of formula I
(Q.A=phenyl; R⁶=CH₃; R⁵=H; Y⁻ = Cl⁻):-

Example	R ¹	R ²	R ⁴	M.P. (°C)	Yield (%)	Recryst. solvent(s)
161	2-MeO-Ph	NH ₂	Et	267-268 ^a + 30		Me ₂ CO/Et ₂ O
162	4-Me-Ph	NH ₂	Et	215-216 ^b	29	Me ₂ CO
163	2-Me-Ph	NH ₂	Et	252-253	19*	EtOH/Et ₂ O
164	3-MeO-Ph	NH ₂	Et	158-160	34	EtOAc
165	4-MeO-Ph	NH ₂	Me	218	22*	Me ₂ CO/Et ₂ O
166	Bu	NH ₂	Et	216-217	12	Me ₂ CO/Et ₂ O
167	Bu ⁱ	NH ₂	Et	280-282 ^c + 19		Me ₂ CO/Et ₂ O
168	Bu	NH ₂	Me	235-237 ^a	8	Me ₂ CO/Et ₂ O
169	Pr ⁱ	NH ₂	Et	213-214	26	Me ₂ CO/Et ₂ O
170	pentyl	NH ₂	Et	199-200	28	Me ₂ CO/Et ₂ O
171	4-MeO-Ph	NHEt	Et	176-177 ^b	42	Me ₂ CO/Et ₂ O
172	4-MeO-Ph	NHMe	Et	223-225 +	15	EtOH/Et ₂ O
173	hexyl	NHMe	Et	148-149	45	Me ₂ O/Et ₂ O
174	PhCH ₂	NHMe	Et	195-196 ^a	66	Me ₂ CO/Et ₂ O
175	Bu ⁱ	NHMe	Et	105-108 ^d	27	Me ₂ CO/Et ₂ O

Example	R ¹	R ²	R ⁴	M.P. (°C)	Yield (%)	Recryst. solvent(s)
176	Bu	NHMe	Et	142-143 ^c	46	EtOAc
177	Pr ⁱ	NHMe	Et	199-200	37	Me ₂ CO/Et ₂ O
178	Pr	NHMe	Et	212-214	22	Me ₂ CO
179	4-MeO-Ph	NHMe	Me	226-228	46	Me ₂ CO
180	hexyl	NHMe	Me	156-158	41	Me ₂ CO/Et ₂ O
181	Bu ⁱ	NHMe	Me	142-146 ^b	21	Pr ⁱ OH/Et ₂ O
182	PhCH ₂	NHMe	Me	208-209 ^b	62	Me ₂ CO/EtOAc
183	Bu	NHMe	Me	164-165 ^a	56	Me ₂ CO/Et ₂ O
184	Pr ⁱ	NHMe	Me	163-164	47	Me ₂ CO/Et ₂ O
185	Pr	NHMe	Me	215-217	18	Me ₂ CO
186	Et	NHMe	Me	225-227	16	Pr ⁱ OH/Et ₂ O

Notes: * characterised as the iodide salt + with decomposition
a: analyses for 0.5 H₂O
b: analyses for 0.25 H₂O
c: analyses for 1.25 H₂O
d: analyses for 0.75 H₂O

The starting 1,2-disubstituted-6-methylpyrimidin-4-ones of formula 6 were obtained in an analogous manner to that described in parts (i)-(iii) of Example 2 that is by reaction of the appropriate 1-substituted-6-methyl-2-methylthiopyrimidin-4-one of the formula 7

(set out hereinafter) with methylammonium acetate, ammonium acetate or ethylammonium acetate, the formula 7 compounds being obtained by methylation of the corresponding thiones of formula 8 (set out hereinafter). The latter thiones were made by analogous procedures to those described in parts (i) and (ii) of Example 3.

The pyrimidin-4-ones of formula 6 had the following properties:-

Formula 6 for Ex.	R ₁	R ²	M.P. (°C)	Yield (%)	Recryst. solvent(s)
161	2-MeO-Ph	NH ₂	255-257	53	EtOH
162,165	4-Me-Ph	NH ₂	297-298	49	EtOH/hexane
163	2-Me-Ph	NH ₂	125-127	45	EtOH/Et ₂ O
164	3-MeO-Ph	NH ₂	258-260	42	EtOH
166,168	Bu	NH ₂	186-187	38	----
167	Bu ⁱ	NH ₂	276-278	30	EtOH
169	Pr ⁱ	NH ₂	242-243	44	EtOH/Pr ⁱ OH
170	pentyl	NH ₂	254-256	40	isolated from EtOH
171	4-MeO-Ph	NHEt	220-225	34	EtOAc/EtOH
172	4-MeO-Ph	NHMe	243-245	38	EtOH/Et ₂ O
173	hexyl	NHMe	135-136	74	Me ₂ CO/Et ₂ O
174	PhCH ₂	NHMe	270-271	83	EtOH

Formula 6 for Ex.	R ₁	R ²	M.P. (°C)	Yield (%)	Recryst. solvent(s)
175	Bu ⁱ	NHMe	135-137	53	----
176	Bu	NHMe	224-225	80	washed with Me ₂ CO
177	Pr ⁱ	NHMe		53	EtOH/Et ₂ O
178	Pr	NHMe	202-203	81	MeCN
186	Et	NHMe	264-266	63	EtOH/Et ₂ O

The methylthio derivatives of formula 7 had the following properties:-

Formula 7 for Example	R ¹	M.P. (°C)	Yield (%)	Recryst. solvent(s)
161	2-MeO-Ph	154-158	68	EtOAc
163	2-Me-Ph	178-179	53	isolated from CH ₂ Cl ₂
164	3-MeO-Ph	173	62	isolated from CH ₂ Cl ₂
166 *	Bu	143-146	77	EtOAc
167 *	Bu ⁱ	87-89	94	trituated with Et ₂ O

Formula 7 for Example	R ¹	M.P. (°C)	Yield (%)	Recryst. solvent(s)
169 *	Pr ⁱ	152-155 (dec.)	85	isolated from EtOAc
170	pentyl	157-158 +	68	isolated from Me ₂ CO
173 *	hexyl	144-145	70	isolated from Me ₂ CO
174 *	PhCH ₂	78-81	58	toluene
178 *	Pr	85-87	72	isolated from EtOH/Et ₂ O
186	Et	185-187	59	EtOH

Note: * also required for other Examples + hydriodide salt

The thiones of formula 8 had the following properties:-

Formula 8 for Example	R ¹	M.P.	Yield	Recryst.
161	2-MeO-Ph	232-234	56	EtOH
163	2-Me-Ph	235-237	83	EtOH
164	3-MeO-Ph	225-227	12	EtOH
165 *	Bu	165-166	46	MeOH
166 *	Bu ⁱ	189-191	35	EtOH/MeOH/H ₂ O

Formula 8 for Example	R ¹	m.p. (°C)	yield (%)	Recrystallisation solvent
169 *	Pr ⁱ	154-157	13	EtOAc
170	pentyl	134-136	44	EtOAc
183*	hexyl	136-137	34	MeOH
184*	PhCH ₂	210-212	55	EtOH

Note: * also required for other Examples

The starting thiones of formula 8 for Examples 178 and 186 were obtained as described by Agai *et alia*, Period. Polytech. Chem. Eng., 1974, 18, 47 and West German OLS No. 252729 (published 8 Jan 1976).

Examples 187-188

The general procedure described in Example 1, was repeated but starting from the known compound 1,6-dimethyl-2-methylamino-pyrimidin-4-one (Agai *et alia*, Period. Polytech. Chem. Eng., 1974, 18, 47) and phosphorus oxychloride to produce the corresponding reactive derivative, which derivative was then reacted with the appropriate amine of the formula Q.A.NHR⁴. There were thus obtained the following compounds of formula I (R¹=R⁶=CH₃):-

(Example 187): 1,6-dimethyl-2-methylamino-4-(N-ethyl-2-(2-methoxy-phenoxyethylamino)pyrimidinium chloride, as a solid, m.p. 170-171°C (recrystallised from acetone) in 40% yield (partial hydrate: 0.5 H₂O; and

(Example 188): 1,6-dimethyl-2-methylamino-4-(N-methyl-2-phenylethyl-amino)pyrimidinium bromide (mixed with 33% chloride), as a solid, m.p. 219-221°C (recrystallised from 2-propanol/ether) in 44% yield.

Examples 189-190

Using a similar procedure to that described in Example 47 but using the appropriate amine of the formula $Q.A.NHR^4$, there were obtained the following compounds of formula I ($R^1=R^6=CH_3$):-

(**Example 189**): 2-amino-1,6-dimethyl-4-(N-methyl-2-phenylethylamino)-pyrimidinium iodide, as a solid, m.p. 168-169°C (recrystallised from 2-propanol/ether) in 45% yield;

(**Example 190**): 2-amino-1,6-dimethyl-4-(N-ethyl-2-(2-methoxyphenoxyethylamino)pyrimidinium iodide, as a solid, m.p. 138-140°C (recrystallised from acetone/water) in 23% yield; and

(**Example 191**): 2-amino-4-(1,2,3,4-tetrahydroisoquinol-2-yl)-1,6-dimethylpyrimidinium bromide, as a solid, m.p. 275-276°C (recrystallised from ethanol) in 12% yield (partial hydrate: 0.25 H₂O).

Example 192

Using a similar procedure to that described in Example 160 but using dimethylamine instead of methylamine, there was obtained 1,2-dimethyl-6-dimethylamino-4-N-ethylanilinopyrimidinium chloride as a glassy solid in 76% yield; NMR(200MHz; d₆-DMSO): 1.16(3H, t, CH₂CH₃), 2.64(3H, s, pyrimidine-2-CH₃), 2.8[6H, s, N(CH₃)₂], 3.65(3H, s, pyrimidine-1-CH₃), 4.06(2H, q, CH₂CH₃), 5.54(1H, br s, pyrimidine-5H), 7.3-7.65(5H, complex, phenyl).

Example 193

The following illustrate representative pharmaceutical dosage forms containing a compound of formula I, or an alternative non-toxic salt thereof, which may be used for therapeutic or prophylactic purpose in humans:-

(a) <u>Tablet</u>	<u>mg/tablet</u>
Compound X.....	50
Lactose Ph.Eur.....	223.75
Croscarmellose sodium.....	6.0
Maize starch.....	15.0
Polyvinylpyrrolidone (5% w/v paste).....	2.25
Magnesium stearate.....	3.0










- 66 -

(b) <u>Capsule</u>	<u>mg/capsule</u>
Compound X.....	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5

"Compound X" stands for a typical compound of the formula I or an alternative non-toxic salt thereof such as is described in any preceding Example herein.









The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets may be coated by conventional means, for example to modify dissolution/disintegration characteristics or improve palatability or stability. For example, a coating of cellulose acetate phthalate may be applied to the tablets to provide a formulation which predominantly releases the majority of the active ingredient in or near the lower alimentary tract.

CHEMICAL FORMULAE



CHEMICAL FORMULAE


(continued)



CLAIMS

What is claimed is:-

1. An aminopyrimidine derivative of the formula I:



wherein R^1 is (1-10C)alkyl, (3-6C)alkenyl, (4-7C)cycloalkyl, phenyl, phenyl(1-4C)alkyl or (3-6C)cycloalkyl-(1-4C)alkyl;
 one of R^2 and R^6 is a basic group selected from amino, (1-6C)alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R^2 and R^6 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl; or both of R^2 and R^6 are basic groups independently selected from the above defined basic groups; and R^5 is hydrogen, (1-4C)alkyl or (3-6C)alkenyl;
 or R^2 is a basic group as defined above, and R^5 and R^6 together form (3-6C)alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring;
 R^4 is hydrogen, (3-6C)cycloalkyl-(1-4C)alkyl, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl or phenyl(1-4C)alkyl; or R^4 is a (1-4C)alkylene or (2-4C)alkenylene linked to the nitrogen atom of the group Q.A.N-, either of which linking groups may optionally bear a (1-4C)alkyl, phenyl or phenyl(1-4C)alkyl substituent and either of which linking groups thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group -A.N-; A is a direct bond to the the group -N(R^4)- or is (1-6C)alkylene or is oxy(2-6C)alkylene in which the oxy group is at least 2 carbon atoms away from the group -N(R^4)-; Q is a pyridyl, furyl, thienyl or phenyl moiety;
 Y is a physiologically acceptable anion;

and wherein any one or more of said phenyl or benzene moieties may optionally be unsubstituted or bear one or more substituents independently selected from halogeno, (1-4C)alkyl, (3-6C)alkenyl, (1-4C)alkoxy, cyano, trifluoromethyl, nitro, carboxy, (1-4C)alkylamino, dialkylamino of up to six carbon atoms, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl and (1-4C)alkylenedioxy;

but excluding those compounds in which:

- (a) R^1 is alkyl, R^2 is amino or alkylamino, R^4 is hydrogen or alkyl, R^5 is hydrogen or alkyl, R^6 is hydrogen or phenyl optionally bearing an alkyl or alkoxy substituent, A is a direct link and Q is phenyl optionally bearing an alkyl or alkoxy substituent;
- (b) R^1 is methyl or ethyl, R^2 is amino, R^4 and R^5 are hydrogen, R^6 is methyl, and Q.A- is unsubstituted phenyl; or
- (c) R^1 , R^5 and R^6 are methyl, R^2 is methylamino, R^4 is hydrogen and Q.A- is 3,5-dimethylphenyl; R^2 is methylthio, R^1 , R^4 and R^6 are methyl; and, in any of which, Y has the meaning stated above.

2. A compound as claimed in claim 1 wherein:

R^1 is methyl, ethyl, propyl, butyl, pentyl, heptyl, allyl, but-2-enyl, but-3-enyl, 2-methyl-2-propenyl, pentenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, 1-phenylethyl, 2-phenylethyl, cyclopropyl-methyl, cyclopentyl-methyl, cyclohexyl-methyl or 2-(cyclohexyl)ethyl;

one of R^2 and R^6 is a basic group selected from amino, methylamino, ethylamino, propylamino, butylamino, dimethylamino, diethylamino, methylpropylamino, dipropylamino, pyrrolidino, piperidino and morpholino; and the other of R^2 and R^6 is hydrogen, methyl, ethyl, propyl, butyl, isobutyl, allyl, but-2-enyl, but-3-enyl, 2-methyl-2-propenyl, pentenyl, methoxymethyl, ethoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, phenyl, benzyl, 1-phenylethyl, 2-phenylethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-methyl, cyclopentyl-methyl, cyclohexyl-methyl or 2-(cyclohexyl)ethyl; or both of R^2 and R^6 are basic groups independently selected from the above defined basic groups; and R^5 is hydrogen, methyl, ethyl, propyl, isopropyl, allyl, but-2-enyl, but-3-enyl or pentenyl;

or R^2 is a basic group as defined above, and R^5 and R^6 together form trimethylene, tetramethylene, pentamethylene or a group of the formula $-\text{CH}_2.\text{C}(\text{CH}_3)_2.\text{CH}_2-$ or $-\text{CH}_2.\text{C}(\text{CH}_3)_2.\text{CH}_2.\text{CH}_2-$, R^5 and R^6 together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring;

R^4 is hydrogen, cyclopropyl-methyl, cyclopentyl-methyl, cyclohexyl-methyl or 2-(cyclohexyl)ethyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, pentyl, allyl, but-2-enyl, but-3-enyl, pentenyl, prop-2-ynyl, but-2-ynyl, benzyl, 1-phenylethyl and 2-phenylethyl; or R^4 is methylene, ethylidene, ethylene, isopropylidene, trimethylene, tetramethylene, vinylene or 1,3-propenylene linked to the nitrogen atom of the group Q.A.N-, any of which linking groups may optionally bear a methyl, ethyl, propyl, butyl, phenyl, benzyl, 1-phenylethyl or 2-phenylethyl substituent and any of which linking groups thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group -A.N-;

A is a direct bond to the the group $-\text{N}(\text{R}^4)-$ or is methylene, ethylene, trimethylene, tetramethylene, any of which may optionally bear one or two methyl substituents, or A is oxyethylene, oxytrimethylene, methyleneoxyethylene or ethyleneoxyethylene, any of which may optionally bear one or two methyl substituents;


Q has the meanings defined in claim 1; Y is a physiologically acceptable anion;

and wherein any one or more of said phenyl or benzene moieties may optionally be unsubstituted or bear one or more substituents independently selected from fluoro, chloro, bromo, methyl, ethyl, propyl, allyl, 2-methyl-2-propenyl, methoxy, ethoxy, propoxy, cyano, trifluormethyl, nitro, carboxy, methylamino, ethylamino, dimethylamino, diethylamino, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, methylsulphonyl, ethylsulphonyl, methylenedioxy and isopropylidenedioxy.

3. A compound as claimed in claim 1 or 2 wherein R^4 is (1-6C)alkyl, A is a direct link and Q is selected from phenyl, 4-chlorophenyl, 4-methylphenyl, 2-nitrophenyl, 2-methylphenyl, 2-carboxyphenyl, 2-methoxyphenyl, 4-methylthiophenyl, 2,5-dinitro-

phenyl, 2,5-dimethylphenyl, 3,5-dimethylphenyl, 3,5-dichlorophenyl, 3,5-dibromophenyl and 3,5-dimethoxyphenyl; or the group of the formula Q.A.N(R⁴)- is selected from 1-indolyl, 3-methyl-1-indolyl, 3-ethyl-1-indolyl, 3-propyl-1-indolyl, 5-bromo-1-indolyl, 5-chloro-1-indolyl, 5-fluoro-1-indolyl, 5-methyl-1-indolyl, 5-methoxy-1-indolyl, 1-indolinyl, 3-methyl-1-indolinyl, 3-ethyl-1-indolinyl, 3-isopropyl-1-indolinyl and 1-indolinyl.

4. A compound of the formula II:





wherein: Ra is (1-10C)alkyl, (3-6C)alkenyl, phenyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl; Rb is (1-6C)alkyl, phenyl, phenyl(1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl-(1-4C)alkyl, amino, (1-4C)alkylamino or dialkylamino of up to 6 carbon atoms; Rc is hydrogen, (3-6C)cycloalkyl-(1-4C)alkyl, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl or phenyl(1-4C)alkyl; or Rc is (1-4C)alkylene or (2-4C)alkenylene linked to the nitrogen atom of the group Qa.Aa.N-, either of which linking groups may optionally bear a (1-4C)alkyl, phenyl or phenyl(1-4C)alkyl substituent and either of which linking groups thereby completes a ring including two adjacent carbon atoms of Q, the atoms of A and the nitrogen of group -Aa.N-; Rd is hydrogen; Re and Rf are independently selected from hydrogen and (1-4C)alkyl, or together form (3-6C)alkylene; Qa is phenyl or pyridyl; Aa is a direct bond to the group -NRc-; Y is a physiologically acceptable anion; and wherein any one or more of said phenyl moieties may optionally be unsubstituted or bear one or more substituents independently selected from halogeno, trifluoromethyl, cyano, nitro, (1-4C)alkyl and (1-4C)alkoxy.

5. A compound as claimed in claim 4 in which Ra is methyl, ethyl, butyl, phenyl or cyclohexyl, Qa is phenyl optionally substituted as defined in claim 4, and Rc is methyl or ethyl.

6. A compound of the formula II wherein Qa is phenyl; Aa is a direct bond to the group -N(Rc)-; Ra is (1-7C)alkyl or (3-6C)alkenyl; Rb is (1-4C)alkyl; Rc is hydrogen, (1-6C)alkyl, (3-6C)cycloalkylmethyl or (3-6C)alkenyl; or Rc is (2-4C)alkylene or (2-4C)alkenylene completing a ring including two adjacent carbon atoms of benzene ring Qa and the nitrogen atom of the group -N(Rc)-; Rd is hydrogen or (1-4C)alkyl; Re and Rf are independently selected from hydrogen and (1-4C)alkyl; Y is a physiologically acceptable anion; and wherein benzene ring Qa may optionally be unsubstituted or bear one or two substituents independently selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy.


7. A compound as claimed in claim 6 wherein Qa is phenyl; Aa is a direct bond to the group -N(Rc)-; Ra is methyl or ethyl; Rb is methyl, ethyl or propyl; Rc is ethyl; or Rc is ethylene or vinylene completing an indoline or indole ring, respectively, including two adjacent carbon atoms of benzene ring Qa and the nitrogen atom of the group -N(Rc)-; Rd is hydrogen or methyl; Re is hydrogen and Rf is methyl or ethyl; Y is a physiologically acceptable anion; and wherein benzene ring Qa may optionally be unsubstituted or bear one or two substituents independently selected from fluoro, chloro, bromo, methyl and methoxy.

8. A non-ionic form of a compound of formula I as defined in claim 1 having the structure Ia or Ib:



(or a tautomeric structure thereof when R⁴ is hydrogen or when the other of R² and R⁶ is amino or alkylamino), wherein "alk" stands for (1-6C)alkyl and R¹, R², R⁴, R⁵ and R⁶ have the meanings defined in claim 1.

9. A non-ionic form of a compound of the formula II as defined in claim 4 having the structure IIa:




in which Ra, Rb, Rc, Rd, Aa and Qa have any of the meanings defined above and "alk" stands for (1-4C)alkyl.

10. A compound as claimed in claim 1, 4 or 6 in which Y is selected from halide, sulphate, fluoroborate, phosphate, nitrate, acetate, benzoate, butyrate, citrate, tartrate, dibenzoyltartrate, fumarate, trifluoroacetate, methosulphate and p-toluenesulphonate.
11. A compound of the formula I as claimed in claim 1 wherein Y is a halide ion and the pyrimidinium counter-cation is selected from 1,6-dimethyl-2-methylamino-4-N-methylanilinopyrimidinium, 1,2-dimethyl-6-methylamino-4-N-ethylanilinopyrimidinium, 1,2-dimethyl-4-(1-indolyl)-6-methylaminopyrimidinium; 1,2-dimethyl-4-(3-methyl-1-indolyl)-6-methylaminopyrimidinium; 1,2-dimethyl-4-(3-ethyl-1-indolyl)-6-methylaminopyrimidinium; 2-ethyl-4-(3-ethyl-1-indolyl)-1-methyl-6-methylaminopyrimidinium; 1,2-dimethyl-6-methylamino-4-(3-propyl-1-indolyl)pyrimidinium; 1,2-dimethyl-4-(3-methyl-1-indolyl)-6-methylaminopyrimidinium iodide; and 1,2-dimethyl-4-(3-ethyl-1-indolyl)-6-methylaminopyrimidinium.
12. The compound 1,2-dimethyl-6-methylamino-4-N-ethylanilino-pyrimidinium chloride or iodide.
13. A process for the manufacture of a compound of the formula I as claimed in claim 1 and wherein R¹, R², R⁴, R⁵, R⁶, A, Q and Y have any of the meanings defined in any preceding claim which is characterised in that:


- 75 -

- a) an amino compound of the formula III:




is reacted with an alkylating agent of the formula $R^1.Z$ in which Z is a suitable leaving group;

- b) a pyrimidinium salt of the formula V:



wherein X is a suitable leaving group, is reacted with an amine of the formula $Q.A.N(R^4)H$; or

- c) for those compounds wherein R^6 is amino, (1-6C)alkylamino, dialkylamino of up to 6 carbon atoms, pyrrolidino, piperidino or morpholino, a pyrimidinium salt of the formula VI:




wherein X is a suitable leaving group is reacted with the appropriate amine selected from ammonia, (1-6C)alkylamine, dialkylamine of up to 6 carbon atoms, pyrrolidine, piperidine and morpholine, or a salt thereof with a (1-4C)alkanoic acid;

whereafter when a different counter-anion Y is required, the compound of formula I is reacted with a suitable metal salt with the desired counter-anion or subjected to ion exchange with a basic resin in the form of its salt with the desired counter-anion.

14. A process for the manufacture of a non-ionic form of a compound of formula I having the structure Ia, Ib or IIa (or a tautomeric structure thereof) as defined in claim 8, which is

characterised by reacting a compound of the formula I wherein one of R^2 or R^6 is amino or (1-6C)alkylamino, and the other of R^2 and R^6 , and R^1 , R^4 , R^5 , Q, A and Y have any of the respective meanings defined therefor in claim 1, by treatment with a strong base.

15. A novel aminopyrimidine of the formula III:



wherein R^2 , R^4 , R^5 , R^6 , A and Q have any of the meanings for novel compounds set out in claim 1.

16. A pharmaceutical composition comprising an active ingredient selected from a compound of the formula I as claimed in claim 1, a non-ionic form thereof having the formula Ia or Ib (or a tautomeric form thereof) as claimed in claim 8, and a non-ionic form of said formula I compound having the formula IIa; together with or in admixture with a pharmaceutically acceptable diluent or carrier.

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 90/00595

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC C 07 D 239/48, C 07 D 239/95, C 07 D 403/04, C 07 D 401/04 IPC ⁵ : C 07 D 471/04, A 61 K 31/505														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;"> Minimum Documentation Searched ⁷ </div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; text-align: left; border-bottom: 1px solid black;">Classification System ¹</th> <th style="width: 70%; text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">IPC⁵</td> <td style="vertical-align: top; padding: 5px;">C 07 D 239/00, C 07 D 403/00, C 07 D 401/00, C 07 D 471/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ </div>			Classification System ¹	Classification Symbols	IPC ⁵	C 07 D 239/00, C 07 D 403/00, C 07 D 401/00, C 07 D 471/00								
Classification System ¹	Classification Symbols													
IPC ⁵	C 07 D 239/00, C 07 D 403/00, C 07 D 401/00, C 07 D 471/00													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Category ¹⁰</th> <th style="width: 70%; text-align: left; border-bottom: 1px solid black;">Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; text-align: left; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> US, A, 4339453 (N. GRIER et al.) 13 July 1982 see column 1, line 67 - column 2, line 55; column 9, line 21 - column 10, line 26; claims 1,2 (cited in the application) <div style="text-align: center;">--</div> </td> <td style="vertical-align: top; padding: 5px;">1,2,10,15</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> EP, A, 0139613 (CIBA-GEIGY AG) 2 May 1985 see pages 1-2; page 22 - page 23, table 1, compound 1.22; page 23 - page 24, table 2, compounds 2.10, 2.12, 2.14, 2.15; claim 1 <div style="text-align: center;">--</div> </td> <td style="vertical-align: top; padding: 5px;">15</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">X</td> <td style="vertical-align: top; padding: 5px;"> DE, A, 3717480 (SHELL AGRAR) 1 December 1988 see claim 1; page 3, line 46 - page 4, line 53; page 8 - page 15, table 1, compounds 15-17, 25, 39, 79 <div style="text-align: center;">--</div> </td> <td style="vertical-align: top; padding: 5px;">15</td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	US, A, 4339453 (N. GRIER et al.) 13 July 1982 see column 1, line 67 - column 2, line 55; column 9, line 21 - column 10, line 26; claims 1,2 (cited in the application) <div style="text-align: center;">--</div>	1,2,10,15	X	EP, A, 0139613 (CIBA-GEIGY AG) 2 May 1985 see pages 1-2; page 22 - page 23, table 1, compound 1.22; page 23 - page 24, table 2, compounds 2.10, 2.12, 2.14, 2.15; claim 1 <div style="text-align: center;">--</div>	15	X	DE, A, 3717480 (SHELL AGRAR) 1 December 1988 see claim 1; page 3, line 46 - page 4, line 53; page 8 - page 15, table 1, compounds 15-17, 25, 39, 79 <div style="text-align: center;">--</div>	15
Category ¹⁰	Citation of Document, ¹¹ with Indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	US, A, 4339453 (N. GRIER et al.) 13 July 1982 see column 1, line 67 - column 2, line 55; column 9, line 21 - column 10, line 26; claims 1,2 (cited in the application) <div style="text-align: center;">--</div>	1,2,10,15												
X	EP, A, 0139613 (CIBA-GEIGY AG) 2 May 1985 see pages 1-2; page 22 - page 23, table 1, compound 1.22; page 23 - page 24, table 2, compounds 2.10, 2.12, 2.14, 2.15; claim 1 <div style="text-align: center;">--</div>	15												
X	DE, A, 3717480 (SHELL AGRAR) 1 December 1988 see claim 1; page 3, line 46 - page 4, line 53; page 8 - page 15, table 1, compounds 15-17, 25, 39, 79 <div style="text-align: center;">--</div>	15												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> ¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family </td> </tr> </table>			¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family										
¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family													
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">6th July 1990</div> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">15.08.90</div> </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div> </td> <td style="vertical-align: top; padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> D. DANIELS </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">6th July 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">15.08.90</div>	International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> D. DANIELS </div>								
Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">6th July 1990</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">15.08.90</div>													
International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> D. DANIELS </div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ¹⁾ with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	US, A, 2845425 (ELI LILLY) 29 July 1958 see column 1, lines 18-34; columns 2-6, examples 2-10,12,13,15,17; claims 1-6 --	15
P,X	EP, A, 0322133 (SMITHKLINE BECKMAN INTERCREDIT B.V.) 28 June 1989 see page 3, lines 5-29; pages 12- 13, examples 8,9; page 19, example 25; page 20, example 27; claims 1-4 --	15
X	GB, A, 1229413 (IMPERIAL CHEMICAL INDUSTRIES) 21 April 1971 see page 1, lines 14-27; page 2, table I, compound 1; claim 1 --	15
X	GB, A, 1502912 (CIBA-GEIGY) 8 March 1978 see page 1, line 23 - page 2, line 5, compound III; page 3, lines 41-46; page 5(b); claim 12 --	15
A	US, A, 4725600 (T. TAKAYA et al.) 16 February 1988 see column 1, line 34 - column 2, line 44 (cited in the application) --	8,15
A	US, A, 2748124 (R.R. BURTNER et al.) 29 May 1956 see column 2, lines 13-31, example 1A; column 3, example 2A; claim 7 -----	15

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9000595
SA 36196

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 01/08/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4339453	13-07-82	None	
EP-A- 0139613	02-05-85	AU-B- 584861	08-06-89
		AU-A- 3245084	07-03-85
		CA-A- 1254560	23-05-89
		JP-A- 60072867	24-04-85
DE-A- 3717480	01-12-88	None	
US-A- 2845425		None	
EP-A- 0322133	28-06-89	AU-A- 2823089	05-07-89
		WO-A- 8905297	15-06-89
GB-A- 1229413	21-04-71	DE-A- 1770637	05-01-72
		FR-A- 1572620	27-06-69
		NL-A- 6808306	16-12-68
		US-A- 3670077	13-06-72
GB-A- 1502912	08-03-78	None	
US-A- 4725600	16-02-88	EP-A- 0168262	15-01-86
		JP-A- 61044872	04-03-86
US-A- 2748124		None	